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ABSTRACT
This work focuses on the development of a candidate material for temporary
synthetic bone. The material is a particulate filled composite based on an unsaturated
linear polyester. The components are mixed with a monomer that cross links the double
bonds of the unsaturated polyester. Degradation occurs via hydrolytic degradation of
backbone polymer's ester linkages. This strategy of prepolymer synthesis via
condensation polymerization in the laboratory followed by cross linking the unsaturated
prepolymer via radical polymerization at surgery offers design flexibility. The radical
polymerization allows curing during surgery to facilitate reconstruction of various
shaped bone defects. The laboratory synthesis of the prepolymer allows alterations of its
composition and physical properties to effect desired properties in the resulting
composite material. The effects of several composite material formulation recipes on
the in vitro mechanical properties and in vivo histologic characteristics of the resulting
material are presented. The prepolymer molecular weight, presence of a leachable salt,
and amount of cross linking monomer had strong effects on the resulting strength and
modulus of the composite. These strengths were of a magnitude appropriate for
consideration of the material as a temporary trabecular bone substitute. The in vivo
studies in a rat proximal tibia model demonstrated progressive growth of new bone
against the receding surface of the degrading material, and insinuation of new bone
trabeculae into the interior of the degrading specimen. There was an absence of a
foreign body inflammatory response to the presence of this material over a five week
time span. The material is an attractive candidate for temporary replacement of
trabecular bone.
Thesis Supervisor: Dr. Robert S. Langer
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CHAPTER 1
The Evolution of Bone Transplantation: Molecular,
Cellular, and Tissue Strategies to Engineer Human
Bone
Introduction
The need to transplant bone to a deficient skeletal location has been
recognized for centuries"' 2. Bone occurs in two forms, trabecular and compact,
and it performs several functions. First, bone is the primary reservoir of calcium
in the body, and exchanges this mineral readily with the extracellular fluid
environment. The concentration of calcium in the body fluids is tightly regulated,
and the supply of calcium in bone is critical to this control. Second, the
hematopoietic marrow that is located in trabecular bone supplies the body's cells,
tissues, and organs with their nutrient carrying red blood cells and infection
fighting white blood cells. Neither of these two functions, however, drives the
need for bone transplantation to a deficient skeletal site. Bone elsewhere in the
skeleton can satisfy these requirements. The third function of bone is its
mechanical role in supporting the body's tissues, and in providing sites of
attachment for the muscles that effect body movement and locomotion. Bone at a
distant location cannot perform this function for a skeletal region that is deficient
in either compact or trabecular bone. The mechanical function of bone, once lost
by injury or other means, can only be regained by restoring skeletal continuity at
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the location of interest.
The restoration of skeletal continuity often involves bone transplantation.
The biologic process that begins with bone transplantation and results in normal
bone structurally and mechanically exploits a unique property of bone. When it is
injured, bone does not heal with a fibrous scar as do virtually all other tissues.
The response of bone to injury is to regenerate bone tissue and then remodel that
newly formed bone in the direction of local stresses. The sequence of bone
regeneration after fracture is similar to the incorporation of transplanted bone at
the recipient site and to the growth of children's bone at the physis (also called the
growth plate). The development of strategies to engineer human bone requires an
understanding of these three processes, because each of them is a manifestation of
the body's evolutionary solution to maintain skeletal integrity. Transplant
incorporation, physeal growth, and fracture healing all result in the formation of
new bone that can then remodel itself to optimize its mechanical function for it's
particular skeletal location. This should be the ideal goal of tissue engineering
strategies to engineer human bone. The initial biomaterial or biomaterial - cell
construct should provide temporary mechanical strength to the reconstructed
region, allow or induce the region to reconstitute itself with new bone, degrade in
a controlled fashion into nontoxic molecules that the body can metabolize or
excrete, and then allow the usual process of remodelling to optimize the
mechanical properties of the newly formed bone.
The final common pathway, that is, the remodelling of newly formed bone
along lines of the local stress field, has a complex mechanism that is only
partially understood more than one hundred years after its discovery 3. The goal of
remodelling is to transform newly formed bone into a mechanically competent
support structure.
After a brief review of the history of bone transplantation, we will
describe the gross and microscopic anatomy of the two types of bone, compact
and trabecular. These two bone types occur in different body locations, and serve
different functions that must be considered when designing systems to regenerate
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bone. We will then discuss several of these systems, which include biodegradable
polymers, cell-polymer constructs, ceramics, glasses, and bone components.
Bioactive molecules are sometimes incorporated into these materials, and the
materials then serve an additional function as delivery systems for the active
molecules.
History of Bone Transplantation
There are several references in the literature to the first recorded bone
graft attempt. Lane' cites a reference by a Dutch surgeon, Job Van Meek'ren2 in
1668. Chase and Herndon' and Gross et a16 mention experiments on periosteal
new bone formation by Duhamel in 1742; their citation for the earliest autograft is
Phillip von Walther in 1820, and their citation for the first allograft is Macewen in
1878. These authors also give the following chronology: Ollier concluded in 1867
that transplanted periosteum and bone remained alive and could become
osteogenic. Prolo and Rodrigo7 place the date of Duhamel's experiments at 1739,
and mention that he implanted subperiosteal silver wires to demonstrate
osteogenesis. Axhausen, in 1909, demonstrated that transplanted bone dies, but
that most periosteum survives and is osteogenic. Senn', in 1889, implanted
hydrochloric acid treated decalcified allograft bone into chronic osteomyelitis
cavities, with the goal of promoting antisepsis within them. He observed
ossification of this tissue from the walls of the defects. Barth8, in 1898, stated that
transplanted bone, marrow, and periosteum die and are replaced by new bone
from the surrounding tissue without prior resorption of the transplanted graft. He
coined the term "schleichender ersatz", which translates from German to English
as "creeping substitution". Axhausen's description in 1909 (see above) was a
correct revision of Barth's initial proposition, and the term schleichender ersatz
was applied to this description. Phemister9, in 1914, described the process of new
bone forming from elements present in bone and utilizing the dead mineralized
framework of bone as a scaffold upon which to grow. This is the process initially
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proposed by Axhausen; Phemister expanded upon it, presented it to the English
language literature, and introduced the English term "creeping substitution". This
application of the term creeping substitution to the process of transplant
resorption and new bone regeneration as described by Axhausen and Phemister is
different than its original meaning as proposed by Barth. Nevertheless, the
Axhausen-Phemister description of the biologic process, and the term creeping
substitution have both persisted to the present time.
Levander"1 injected extracts of bone into muscle and demonstrated the
formation of new bone in the heterotopic muscle site. This report, from the
1930's, demonstrates early thoughts on the induction of osteogenesis by some
factor present in the bone transplant. It was approximately three decades from his
publication until the demonstration in 1965 by Urist" that an extract of
demineralized bone matrix could cause invading mesenchymal cells from the host
to become osteoblasts and make new bone in a heterotopic site. The quest to
identify this putative bone morphogenetic protein (BMP) lasted more than another
two decades. The isolation and biochemical sequencing of BMP occurred in
198912, and its production by recombinant DNA technology became a reality
soon afterwards"3 . There are seven different BMP's that have been identified, and
they are called BMP-1 through BMP-7. The activity associated with Urist's
observations in 1965 is possessed by BMP-2.
The historical trail of bone transplantation has led us to this point: the
successful regeneration of bone requires cells that will produce osteoid (bone
matrix) , an appropriate scaffold upon which the new bone can grow, and
bioactive molecules to direct the process. The host must, of course, provide a
vascular supply and nutrients. The transplanted construct must usually impart
some mechanical properties to the reconstructed region, and these can be
approximated by the mechanical properties of the bone being replaced. The exact
mechanical requirements are dictated by the anatomy, functional loading, and
clinical circumstances of a particular reconstruction. The technology now exists
to address each of the required bone regeneration components separately 4"15. The
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evolution of bone transplantation is now entering an era where novel
combinations of the required constituents and equally novel processes to deliver
them are undergoing experimentation.
Bone Anatomy
Mature bone exists as compact bone or as trabecular bone. Compact bone
is also called cortical bone, and trabecular bone is also called cancellous or
spongy bone. Compact bone is distinguished from trabecular bone by the spatial
orientation of its mineral and organic elements, and by its characteristic locations
in the skeleton. Compact bone comprises the outer tubular shell of the long bones,
and the outer surface of the small bones and flat bones. It is much more dense
than trabecular bone, and it consists of parallel cylindrical units called osteons (or
Haversian systems). Compact bone is anisotropic, and the orientation of the
osteons determines, to a great extent, the directionality of its mechanical
properties. Trabecular bone is less dense than compact bone, and occurs near the
ends of long bones, as the interior of small bones, and between the surfaces of flat
bones. Trabecular bone is comprised of an array of plates and rods of bone tissue,
and forms an open celled foam'". The orientation of the plates and rods is such
that the trabecular bone is also anisotropic. It optimizes resistance to the usual
stresses that occur in its particular location. Long bones are described by regions:
diaphysis, metaphysis, and epiphysis. These descriptive terms use the physis, or
growth plate, as their reference point. The physis is the specialized region near
each end of a long bone from which longitudinal and appositional growth of the
bone occur. The epiphysis ("upon the physis") is the portion of the long bone
between the physis and the end of the bone. It is covered with the articular
cartilage that allows the joint to move with low friction. The metaphysis ("next to
the physis") is the transition from the wide part of the bone near the joint to the
tubular part of the bone near the bone's center. The diaphysis ("far from the
physis" or "between the physes") is the tubular center region of a long bone that
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lies between the expansions at either end. After skeletal maturity, the physis no
longer exists, but these three terms are still used to identify the region of interest
in a long bone. These terms are not used in the discussion of either flat or small
non-tubular bones.
Mature bone is lamellar bone. New bone, whether formed at the physis,
during fracture repair, in neoplasia, in embryonic life, or as a result of bone graft
incorporation, is woven bone. Woven bone becomes lamellar bone through the
process of remodelling. The randomly oriented collagen fibers of woven bone
become parallel fibers in lamellar bone. The mineral phase that accompanies
these collagen fibers is directional: this organized, remodelled mineral phase
gives lamellar bone its anisotropic properties. This is true in the organized
lamellar osteons of compact bone and in the organized plates and rods that
constitute the open cellular foam structure of trabecular bone.
Newly formed bone is also described by its developmental origin: it has
formed via either intramembranous ossification or endochondral ossification.
Intramembranous ossification is the formation of woven bone directly from
condensed mesenchymal tissue without the intermediate formation of a
cartilaginous framework of the future bone. Endochondral ossification involves a
cartilaginous intermediate formed from mesenchymal tissue. This cartilage
framework is then ossified to form the new bone. Intramembranous ossification
occurs primarily in the embryonic formation of the flat bones (e.g. skull), and, in
part, the clavicle. Endochondral ossification occurs in the embryonic formation of
the long bones, in fracture repair, in physeal growth of the immature skeleton, and
in the incorporation of bone grafts. Note that the term ossification imparts a
special meaning that is not conveyed by the two related terms calcification and
mineralization. Calcification is a term that indicates deposition of calcium salts in
tissues. This deposition is not in any particular pattern, and occurs because the
tissue concentration of the calcium salt has exceeded the solubility limit for that
salt. It can continue unabated, limited only by the supply of calcium in excess of
the solubility limit and the density that the deposited salts can attain. Ossification
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is the orderly deposition of calcium salts into predetermined locations on a
collagenous framework called osteoid. The osteoid is laid down by the bone
forming osteoblast cells. The calcium salts deposited in this fashion form
hydroxyapatite, the mineral phase of bone. Mineralization is the most general of
the three terms, and refers to the deposition of mineral salts in tissue via either
calcification or ossification. The outer surface of bones is covered by a
connective tissue called periosteum. This tissue is thicker in children, and is less
prominent in adults. Its inner layer, the cambium layer, contains cells that can
become osteoblasts and make bone"7 .
The normal anatomy of bone is a result of evolutionary functional
optimization via structural adaptation. When we describe various tissue
engineering strategies to regenerate bone, it will be productive to frequently
return to and review this anatomy. We can consider the contributions of each of
these natural components to the function of bone as we attempt to discover
acceptable substitutes for those functions.
Normal Fracture Healing
A bone fracture disrupts skeletal continuity and mechanical function,
injures local blood vessels, and initiates the process of fracture repair. This
process can be described by a combination of its three biologic stages'8 and its
four biomechanical stages"9 . The biologic stages are inflammation, repair, and
remodelling. They recapitulate the endochondral ossification that occurs during
intrauterine growth. The first event that occurs after a fracture is the escape of
blood from damaged vessels, and the formation of a hematoma at the fracture site.
This hematoma organizes; that is, the body's coagulation cascade becomes
activated, and it attempts to stop the hemorrhage by clotting the blood. A fibrin
clot forms, platelets in the blood attach to it, and they release vasoactive
mediators and growth factors. Acute inflammatory cells arrive at the site and
remove necrotic tissue. Polymorphonuclear leucocytes are the first inflammatory
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cells to arrive, and are followed by macrophages. Inflammation is the shortest
phase in the repair process, and is followed by repair. The process of repair
consists of the cellular synthesis of new bone organic matrix, and the ossification
of that matrix to form new woven bone. The osteoblasts that make the new matrix
originate in pluripotential mesenchymal cells. These cells are derived from both
the site of injury and from distant sites via the bloodstream. The inner layer of the
periosteum, called the cambium layer, likely contributes the first cells to the
repair process. The combination of osteoblasts, cartilaginous matrix, and woven
bone is called fracture callus. This callus is the product of fracture repair, and is
the new raw material for fracture remodelling. Remodelling is the third and
longest biologic stage of fracture healing. During this phase, the woven bone
undergoes sequential resorption and deposition to become more organized
lamellar bone. This results in bone whose organic and mineral phases are better
aligned to resist local stresses.
The four biomechanical stages of fracture healing were determined by
testing healing fractures to failure in torsion". The types of failure that were
observed reflected increasing strength of the healing fracture site as it passed
through the three biologic stages of healing. In the first biomechanical stage,
refracture of the healing fracture under torsional load occurs through the original
fracture site with low stiffness compared to the characteristic stiffness of the
uninjured bone. In the second stage, the refracture still occurs through the original
fracture site, but the stiffness has increased to a range characteristic of hard tissue.
In biomechanical stage three of healing, the refracture occurs partly through the
original fracture site, and partly through previously intact bone. The stiffness is of
the order of magnitude of hard tissue, as it was in stage two. In stage four, the
location of the fracture is not related to the site of the original injury. A stage four
refracture pattern indicates that remodelling has restored the original mechanical
properties to the injured tissues. In clinical practice, many injury variables, patient
variables, and treatment variables influence the time that each of these stages
requires. In general, remodelling of a major long bone fracture will take a time
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interval on the order of a year to return the bone to its prefracture strength. We
will now see that the fracture healing process bears striking similarities to the
endochondral ossification that occurs at the physis of skeletally immature bones.
Skeletal Growth at the Physis
Long bones in a child increase both their length and diameter via growth
at a specialized cartilaginous region near their ends called the physis or growth
plate. The formation of new woven bone at the physis occurs via endochondral
ossification. Appositional remodelling of the diaphysis occurs via
intramembranous ossification. We now discuss the physeal growth and its
similarities to fracture healing and incorporation of bone transplants.
The physis can be described by functional and anatomic zones20 . The
functional zones, beginning at the epiphyseal end, are the zones of growth,
maturation, transformation, and remodelling. The functional zones can be further
described by anatomic regions. The growth zone contains cells that are in
germinal, proliferative, and columnation regions. The maturation zone contains
the cellular hypertrophy and calcification regions. The transformation zone
contains the vascular penetration and ossification regions. The remodelling zone
is the junction between physis and metaphysis, and consists of the primary and
secondary spongiosa.
The cells in the growth zone begin to divide, secrete extracellular cartilage
matrix, and line up in columns. This increases the length of the bone by a
combination of increased number of cartilage cells and an increased amount of
intercellular matrix. This increased length of cartilage is the framework for
subsequent endochondral ossification. The bone widens at the physis by a
contribution of cells from a specialized area of the growth zone called the groove
of Ranvier. The columns of cartilage cells are separated from each other by
longitudinal bars of cartilage matrix; cells in each column are similarly separated
by transverse bars of cartilage matrix. As newly divided cells are added to the top
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of each lengthening column, the cells further down the column begin to enlarge
(hypertrophy), and secrete matrix vesicles. These vesicles are the sites of initial
calcification of the cartilage matrix. The calcified cartilage matrix furthest from
the zone of growth is invaded by the ingrowth of blood vessels from the
metaphysis. This vascular invasion brings cells and biomolecules that remove the
last transverse cartilage bar which separates physis from metaphysis. This area
now becomes metaphysis, and osteoblasts deposit bone matrix (osteoid) on the
calcified cartilage bars. This region has ossified, and consists of woven bone
called the primary spongiosa. This woven bone is remodelled, just as the initial
woven bone in fracture healing is remodelled. The remodelled woven bone is
termed the secondary spongiosa. A rather striking exhibition of remodelling
occurs during physeal growth. The physis, and hence the ends of long bones, are
wider than the diaphysis, or shaft of those bones. The narrow, tubular shaft is a
mechanically optimized structure for bearing the loads that it experiences. The
newly formed metaphyseal bone is the same diameter as the physis that made it
and that is growing away from it. Sequential resorption of woven bone from the
metaphysis' outer surface and deposition of lamellar bone on its inner surface
decreases its diameter as it becomes diaphysis.
The above description is an intentionally brief narrative of a complex
process. The pertinent points for this discussion are that remodelled bone occurs
through a process that begins with a source of committed cells that form a
cartilaginous precursor of the eventual bony region. The cells then die, and an
ingrowing vascular supply brings cells and biomolecules that cause bone
extracellular matrix to occur throughout the cartilaginous framework. This matrix
ossifies, and is then woven bone which, via a process of resorption and
reossification, becomes remodelled lamellar bone. We now discuss bone
transplant incorporation, and its similarities to both fracture healing and physeal
growth.
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The Biology of Bone Graft Incorporation
The clinical "gold standard" for bone transplantation is the autogenous
trabecular graft. Allografts and autogenous compact grafts incorporate via the
same general scheme as autogenous trabecular grafts, but they have some
important differences. We begin with a description of autogenous trabecular graft
incorporation. The transplantation of the graft invariably injures local vessels, and
leaves bleeding host trabecular bone at the recipient site. This activates the blood
clotting cascade, and a fibrin clot forms. The clot organizes into fibrous
granulation tissue, and attracts both inflammatory cells and new vascular tissue.
The elements of the trabecular graft undergo necrosis. There is controversy over
whether the cellular elements live and contribute to osteogenesis, but their
contribution, if present, is likely small compared to that of the host tissues"7 . The
trabecular graft begins to revascularize within hours of transplantation, and
revascularization is usually complete in two weeks. New fibrovascular
granulation tissue moves through the porous trabecular network and occupies the
graft. Osteoblasts, the bone forming cells, appear with the vascular tissue.
Mesenchymal osteoprogenitor cells differentiate to become the osteoblasts. There
are several candidates for the mesenchymal cells that become osteoblasts 7.
These include vascular endothelial cells, circulating monocytes,
reticuloendothelial system cells, and fibroblasts. The invasion of the graft by
neovascularization, followed by the appearance of bone forming cells in the
region, mimics the situation that was discussed above for physeal growth. Recall
that, at the physis, vascular channels in the metaphysis broke through the last
transverse cartilaginous septum which separated metaphysis from physis. This
vascular invasion then brought osteoblasts that deposited osteoid on the calcified
cartilage bars of the physis. The trabecular graft has an open porous structure that
permits the deposition of new bone directly on necrotic trabeculae. The
transplanted trabeculae do not lose their mechanical strength when they die.
Therefore, a trabecular graft undergoes an initial increase in mechanical strength
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as new bone is deposited on existing necrotic trabeculae. Then, as the necrotic
trabeculae are later remodelled, the strength of the incorporated transplant
decreases toward that of normal trabecular bone. This sequence is one of three
differences between the incorporation of trabecular and compact grafts. Heiple21
has reported 25 years experience with the dog ulna model for investigation of
trabecular transplant biology. This model is a segmental defect in the ulna, uses
the contralateral ulna as a control, and does not use internal fixation. Heiple states
that, in this model, trabecular autograft transplants are revascularized completely
and have fibrous tissue continuity two weeks post transplantation. They are
completely filled with new bone or a bone-cartilage combination by two months,
and are already remodelling the new woven bone to lamellar bone at that time.
The three important differences in the sequence of incorporation between
trabecular and compact bone transplants have implications for the clinical
management of patients after transplantation of compact or trabecular bone. The
differences lie in the rate of transplant revascularization, the osteoblastic vs.
osteoclastic response, and the completeness of the repair. They must be
considered when designing materials and strategies to replace bone.
The sequence of graft incorporation is similar for compact and trabecular
transplants during the first two weeks. The formation of the hematoma, and its
organization into a fibrin clot are identical in the compact and trabecular cases.
The trabecular transplant is revascularized much more rapidly than the compact
bone transplant. Revascularization of the trabecular graft occurs through the open
marrow spaces. The same process in the compact graft must occur through
existing haversian canals. The porosity that these haversian systems (osteons)
confer upon compact bone is low compared to the porosity of trabecular bone.
The ingrowth of new blood vessels through the haversian canals takes much
longer than the ingrowth of new vessels through the open pores of trabecular
bone. Compact autogenous grafts may require two months to revascularize7
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compared to two weeks for trabecular grafts.
The second difference between the processes of compact and trabecular
transplant incorporation lies in the sequence of new bone substitution for the
necrotic transplant. We mentioned above that the host response to a trabecular
graft is osteoblastic. That is, the trabecular graft has new woven bone form on its
necrotic trabeculae without prior resorption of those trabeculae. The necrotic
compact graft, however, causes the host to resorb parts of it before any new bone
is laid down. Therefore, osteoclasts, which resorb bone, act before osteoblasts
make new woven bone in the presence of a compact bone transplant. The
importance of this difference is that compact transplants, often used to treat large
segmental bone defects, undergo a stage of decreased mechanical strength. This
occurs between approximately six weeks and six months post-transplantation,
when the initial resorptive (osteoclastic) phase has outstripped the appositional
(osteoblastic) phase of compact transplant incorporation". Compact transplants
can lose 50% of their strength in six months, and this loss is reversed over one to
two years7.
The third difference between the two incorporation processes is the
completeness of the repair. The transplanted trabeculae of trabecular grafts are
completely resorbed during remodelling, and the entire repaired region becomes
remodelled lamellar bone. Compact grafts remain an admixture of necrotic and
viable bone for years, and may never completely become new bone17 . The
residual necrotic bone in a compact transplant may be 50-90% of the original
graft many years after transplantation7 . The significance is that, although the
necrotic graft retains its strength, the region of space that it occupies cannot
undergo complete remodelling, and therefore may not contain optimally oriented
bone for its mechanical needs.
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Biomechanics of Trabecular and Compact Bone
Bone needs to resist the loads placed on the skeleton during the activities
of living. Many such loads have been estimated, and they place compressive,
tensile, and shear forces on the bone22'23. Trabecular bone functions mostly in
compression, but its strength and modulus are approximately the same in both
tensile and compressive loading. Compact bone functions in compression,
tension, and shear. The mineral phase of compact bone imparts strength in
compression and shear, and its collagen fibers provide tensile strength. Compact
bone, in the form of oriented remodelled haversian systems (osteons), forms the
tubular cortices of long bones. These bones are loaded primarily by compressive
forces at their ends. This loading configuration, however, imparts both bending
and torsional moments to the long bones. When we consider strategies to replace
the mechanical function of bone, it behooves us to consider the forces that any
replacement material will experience. The experimentally determined strengths
and moduli of compact and trabecular bone provide a useful measure of
appropriate strengths and moduli for replacement materials. These values appear
below, and have been collected from several sources22 25.
Compact bone is anisotropic. The measured strength depends on the
orientation of the applied test loads with respect to the direction of the osteons.
The ranges of reported strengths of compact bone, when tested in a longitudinal
direction (parallel to the long axis of the osteons) are: 78.8-151 MegaPascals
(MPa) in tension, and 131-224 MPa in compression. Compact bone strength
ranges, when tested in a transverse direction (perpendicular to the long axis of the
osteons) are: 51-56 MPa in tension, and 106-133 MPa in compression. The range
of reported shear strengths of compact bone (tested in torsion) is 53.1-70 MPa.
The reported ranges of moduli (Young's modulus) for compact bone are as
follows. The longitudinal modulus range (both tension and compression) is 17-20
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GigaPascals (GPa). The transverse modulus range is 6-13 GPa. The reported
shear modulus is 3.3 GPa.
The strengths and moduli for trabecular bone are related to the apparent
density of trabecular bone by a power law function 22. The density of human
trabecular bone varies from approximately 0.1 grams per cubic centimeter up to
1.0 grams per cubic centimeter. For comparison, compact bone has a density of
approximately 1.8 grams per cubic centimeter. A trabecular bone specimen with a
density of 0.2 grams per cubic centimeter has a porosity of about 90%. The
strength of trabecular bone varies widely over the range of observed densities.
The strength varies as the square of the apparent density, and the modulus varies
as either the square or cube of the apparent density. The strength and modulus are
both sensitive to the rate of loading. This is a manifestation of the viscoelastic
nature of bone. Midrange values for trabecular bone strength and modulus that
can serve as design goals for replacement materials are 5-10 MPa strength and
50-100 MPa modulus26.
We have discussed the mechanisms that the body uses to produce
remodelled, structurally competent bone. We have also reviewed the mechanical
properties of compact and trabecular bone that are representative of that structural
competence. We now discuss several strategies that are alternatives to compact
and trabecular bone transplantation. The techniques reviewed here will be geared
toward orthopaedic applications, although they can also be considered in the
context of craniomaxillofacial applications. The biologic principles are identical
in the two classes of applications, but the load bearing requirements are somewhat
different 4.
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Strategies for Bone Regeneration
The variety of reported novel techniques to regenerate bone make use of
polymers, ceramics, transplanted cells, and bioactive molecules. These
components have been used in different combinations with each other and with
transplanted bone. Lane's review' states that "it is crucial that potential graft
substances be experimentally characterized in terms of their precise contributions
to the bone-forming mechanisms." We will now discuss several potential
solutions to the problem of bone regeneration, and how each of them addresses
this statement.
There have been a variety of animal models used for the evaluation of
bone replacement materials, and have included rodents26' 27, rabbits 27,28 ,29,
dogs4,21,30, and non-human primates3 1'3 2. The choice of model involves decisions
concerning cost, stage of development of the particular material, and the intended
application for the material. There have been models proposed and used that are
specific for craniomaxillofacial applications33 , orthopaedic trabecular bone
applications21' 27, and orthopaedic cortical (compact) bone applications ' .
Preliminary investigations of a novel material might typically begin in a rodent
model. After initial demonstration of a promising material, the evaluation
progresses to a higher animal model. This allows data collection in a skeletal
system whose bone physiology and mechanical loading characteristics (for
orthopaedic applications and some craniofacial applications) more closely mimics
those of humans. Ripamonti has suggested that a material should ultimately
undergo nonhuman primate evaluation prior to any human use32. The common
theme in all the models is that they include a skeletal defect that will predictably
not heal, in the majority of cases, in the lifetime of the animal33. The exceptions to
this rule are some of the rodent models used for early feasibility and
biocompatibility testing of a new material26' 27.
-28-
Polymers
The strategies that include polymers exploit two of their attractive
properties. First, there is great design flexibility, because the polymer
composition and structure can be tailored to the specific need. Novel polymer
synthesis is often the first step in material selection and formulation. The second
useful polymer property is biodegradation. Polymers can include chemical bonds
that undergo hydrolysis upon exposure to the body's aqueous environment, and
they can also degrade by cellular or enzymatic pathways. The degradation rate is
amenable to control by alterations in polymer properties such as hydrophobicity
and crystallinity. Polymeric systems that have been investigated for bone
regeneration include the poly (a-hydroxy esters) 29' 3 4'3 5'36, polydioxanone37
poly(propylene fumarate) 26, poly (ethylene glycol) (PEG)29, poly (orthoesters)38
polyanhydrides3 9, and polyurethanes40 . The most frequently investigated poly (a-
hydroxy esters) have been poly (L-lactic acid) (PLLA), poly (glycolic acid)
(PGA), and poly (lactic-co-glycolic acid) (PLGA). These three materials, along
with polydioxanone, have a long history of use as degradable surgical sutures, are
approved for human use by the Food and Drug Administration, and are
reasonably biocompatible.
Polydioxanone has been combined in semi-rigid sheet form with
demineralized bone matrix (DBM) in rat calvarial defects. It functioned as a
restraining agent for the particulate DBM, and provided shape control37 .
Polyurethane, in membrane form, was used to form a tube around a rabbit radius
defect"4 . Ten of ten defects healed, compared to one of ten untreated contralateral
controls. This is an example of the "guided tissue regeneration" principle, in
which the tube of polymer is purported to prevent the ingress and ingrowth of
tissues different from the injured tissue during healing. Polymers of silicon
(glasses) have been combined with DBM, and demonstrated faster bone
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regeneration than DBM alone". PLLA has been copolymerized with PEG to
yield a low viscosity material that can be injected through a syringe. The addition
of PLGA to make a PLLA-PEG-PLGA terpolymer results in a firmer, moldable
material. These polymers have been used as delivery systems for bioactive
molecules29. Poly (propylene fumarate) (PPF) has been incorporated into
composite materials to replace trabecular bone26' 42, and to deliver antibiotics to
bone in high local concentration43 . The fumaric acid double bond of the polymer
chain has been used to secondarily cross link the PPF during formulation of the
composite material. This material has demonstrated adequate mechanical
properties in vitro to function as a temporary trabecular bone replacement 444 5.
Ceramics
The use of ceramics in bone regeneration applications is based upon their
structural similarity to hydroxyapatite, the mineral phase of bone. The two most
commonly investigated ceramics have been p-tricalcium phosphate (P-TCP) and
synthetic hydroxyapatite (HA)46 . These materials are osteoconductive: they
provide an appropriate open cell porous structure onto which osteoblasts can
deposit bone4 '. They are biocompatible"4 . They differ in several aspects, one of
which is the rate of resorption. HA resorbs very slowly compared to p-TCP30.4 9 .
In a proximal tibial and distal femoral model, only 5.4% of HA had resorbed at
three months compared to 85% resorption of p-TCP during the same time
period 49. Various authors have considered HA, and hence its slow resorption
relative to the characteristic time span for bone regeneration, to be both an asset"o
and a liability". The argument against HA is that the new bone, once formed in
the porous network of the HA scaffold, cannot experience the mechanical loading
that it needs to remodel if the HA remains strong. Long term persistence of
remodeled bone would be more likely to occur if the initial scaffold would
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degrade and allow the bone to be loaded. The argument in favor of HA is that its
structure more closely resembles natural bone hydroxyapatite than does that of P-
TCP, and therefore it represents a better scaffold for bone ingrowth. P-TCP is a
multicrystalline, porous ceramic, and is not identical to tribasic calcium
phosphate"4 . A natural source of HA from coral (Porites species) has been used in
bone regeneration studies30'"51. This coralline HA has also been used as a mold to
synthesize HA by a technique called the replamineform process.
Coralline HA was used as a delivery vehicle for osteogenin, one of the
family of bone morphogenetic proteins (BMP's), in a rat calvarial study ". There
were four experimental groups: HA plus osteogenin, HA alone, empty control
defects, and collagen plus osteogenin. Only the collagen plus osteogenin group
formed significant bone in the defect, and the authors hypothesized that perhaps
the relatively nonresorbable HA released osteogenin less well than did P-TCP.
The use of coralline HA in a dog radius model resulted in complete filling of the
HA pores with new bone at three months. There was no degradation of the
original quantity of HA at the three month time point 3° .
Bioactive Molecules
The identification of human bone morphogenetic protein'2 and its
production by recombinant DNA technology" has ushered in the development of
novel systems to deliver it to bone repair sites in an effective manner. BMP has
been delivered to a segmental rabbit tibial defect via a polymer containing PLLA,
PEG, and PLGA2 9. There was complete restoration of the defect in twelve weeks.
Mechanical strength in this model was supplied by an HA rod spanning the defect
and an external skeletal fixator. The polymeric material was used solely as a BMP
delivery system. Two dosages of BMP-2 (1.4 jig and 11 jig) were tested in a rat
femoral defect model52. The carrier was rat DBM, and contralateral control
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defects contained DBM without BMP. The high dose group had ten often
segmental defects heal. None of the defects healed in either the low dose group or
the DBM controls. Other carriers have included a PLGA-TCP composite53 ,
collagen 54 , plaster of paris55 , and HA impregnated with collagen56 . These systems
produced new bone in heterotopic sites, and demonstrated more bone with
increasing BMP doses.
In a study of BMP delivery to treat nonunions"7, four patients with distal
tibial metaphyseal nonunions who were at the point of amputation as their next
step in management were treated with human allogenous BMP in a PLLA-PLGA
delivery system. BMP represented 0.00 1% of the fresh weight of donor bone, and
was extracted with other noncollagenous proteins. All four patients healed their
nonunions within five months after this treatment.
Cellular Transplantation
The delivery of bioactive molecules to the site of bone repair assumes that
those molecules will act upon mesenchymal cells, cause those cells to migrate to
the site, differentiate, and express bone forming function. Several approaches to
bone regeneration envision the delivery of the cells themselves to the repair site.
Osteoblasts have grown on poly (a- hydroxy esters) and expressed their
phenotype, as measured by production of alkaline phosphatase and type 1
collagen". An osteoblast like cell line (MC3T3-E1) was grown on both the poly
(a- hydroxy esters) and the polyphosphazines, and the cells retained their
phenotypic expression". One strategy used harvested autologous chondrocytes,
and expanded their numbers by cell culture into porous HA. The composite of HA
plus cells was then implanted into a rabbit ulna defect 28. The rabbit has a
synostotic radius and ulna, and therefore required no internal fixation of the
defect. The study demonstrated bone formation at twelve weeks. There was no
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bone in the contralateral defect, which contained HA as a control. The rationale
for this approach is that chondrocytes are easier to culture than osteoblasts.
Cartilage is aneural, alymphatic, and avascular. The nutrition of cartilage occurs
by diffusion. These cells, once transplanted into the bone repair site, must make
the cartilage matrix that forms the scaffold for endochondral ossification.
Summary
The need to replace bone when the body's repair mechanism fails has
existed for a long time, and will, in all probability, continue to do so. The
eventual solution to this problem will likely contain some of the concepts that
have been reviewed here. The necessary elements of the solution should, we
believe, include the following items. First, the material that initially re-establishes
the injured skeleton's mechanical integrity should be a temporary material. This is
necessary because the bone that forms must be allowed to bear load, and remodel
in response to that load. An integral part of this requirement, for Orthopaedic
applications, is that the mechanical properties of the material be adequate to
perform the function of the type of bone it replaces. Second, the material must
degrade in a controlled fashion into nontoxic products that the body can
metabolize or excrete via normal physiologic mechanisms. Third, a vascular
supply must be re-established into the reconstructed region to bring nutrients,
cellular precursors, and bioactive molecules to the region, and to remove
metabolic wastes and necrotic debris. Note that some of the potential solutions
include cells and bioactive molecules, but the nutritional and waste removal
functions of the vasculature are still necessary. Finally, consideration should be
given to the intended clinical use of the materials. This will insure that material
variables such as shelf life, time period between identified need and availability,
and handling properties receive due thought during the design phase. Similarly,
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the design phase should include surgical considerations such as the required
operative exposure, alterations to existing surgical techniques that a new material
may impose, and post-surgical rehabilitation differences that may be necessary.
These will probably be easier to consider during the design than to retrofit at a
later time.
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CHAPTER 2
Two Stage Synthesis of Poly (Propylene Fumarate)
via Initial Schotten-Baumann Reaction Followed
by Transesterification of Trimer to Polymer.
Introduction
Poly (propylene fumarate) (PPF) has undergone development as a
candidate polymer for use in a biodegradable composite material for Orthopaedic
applications. Prior methods of synthesis employed harsh reaction conditions that
made it difficult to obtain reproducible product. This work involves a novel
synthesis technique to produce PPF. The process is an initial Schotten-Baumann
reaction between the diacid chloride of fumaric acid and propylene glycol to
produce a trimer. The trimer, bis-(hydroxypropyl) fumarate, then undergoes a self
transesterification to form the polymer. The reaction is reproducible, simple to
carry out, and avoids the previous severe reaction conditions that led to
undesirable side products. We suggest that it represents an attractive method to
synthesize this polymer for subsequent use in composite materials for
Orthopaedic applications.
Bone is a unique tissue in its response to injury. Tissues in the body, when
injured, progress through a process of inflammation and repair that results in scar
tissue at the site of injury. An injury to bone (that is, a fracture) initially responds
in a manner similar to that of other tissues, but an important difference in the
healing process occurs: the evolving repair tissue becomes bone instead of scar.
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The motivation for this work is to exploit bone's inherent self healing ability by
developing a material that can provide structural support to a region of the
skeleton and be biocompatible, degrading in a controlled fashion into non-toxic
substances that the body can eliminate via normal metabolic pathways. Poly
(propylene fumarate) (PPF) has been investigated60' 61' 62' 42' 63,44,45 as a backbone
polymer for use in a composite material to address the need for a temporary bone
substitute. PPF is an alternating copolymer of propylene glycol and fumaric acid.
The attractive features of PPF for this application include the double bond that is
present in each fumarate structural unit, the ester linkage between each structural
unit, and the nature of the two monomers that comprise the repeating unit. The
double bond makes the polymer amenable to crosslinking via radical
polymerization at the time of composite material formation. This offers the
capability to mix the sterilized components of the composite material during an
operation, and have the material pass through a moldable putty stage. The putty
stage is quite useful for filling irregularly shaped defects in bone. The second
property mentioned above, the ester linkage, is the basis for in vivo degradation of
the polymer. The equilibrium nature of stepwise condensation polymerization
results in ester hydrolysis upon exposure to the body's aqueous environment 45 .
The rate of degradation of the composite material can be controlled by varying the
PPF molecular weight and the hydrophilicity of its immediate environment
(determined by other ingredients of the composite formulation). The third
attractive property of PPF, i.e. the nature of its monomers, is related to
biocompatibility. If the assumption is made that the polymer will degrade in vivo
to its constituent monomers (an assumption that will need to be checked later),
then those monomers must be compatible with the human body. They must not be
toxic, and the body must be able to metabolize or excrete them via normal
physiologic pathways. The two monomers that comprise PPF are propylene
glycol and fumaric acid. Propylene glycol is widely used as a diluent in
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intravenous fluids, and fumaric acid is a component of the physiologic Krebs
cycle of human metabolism.
Poly (propylene fumarate) has been synthesized by several methods 44' 6 '62 .
Each method has had drawbacks, including long reaction times, exacting
polymerization conditions, and the presence of side reactions. The motivation for
this work was to devise a quicker, more reproducible method of synthesizing PPF.
Materials and Methods
The synthesis strategy involves an initial Schotten-Baumann reaction
between a diacid chloride (fumaryl chloride, CI-CO-CH=CH-CO-Cl) and a
dialcohol (propylene glycol, HO-CH 2-CHOH-CH 3). This is a rapid, irreversible
reaction that is performed at room temperature and atmospheric pressure. There is
no catalyst, and the HCI that is produced is trapped by bubbling it through
aqueous NaOH. The reaction is run with an excess of propylene glycol (Aldrich
Chemical Company, St. Louis, MO), and produces the trimer, bis-
(hydroxypropyl) fumarate. Figure 2-1 demonstrates the reaction sequence. The
fumaryl chloride (Aldrich Chemical Company, St. Louis, MO) and propylene
glycol (Fisher Scientific, Pittsburgh, PA) were reagent grade and were distilled
prior to use. First, 5.6 moles (426 gm) of propylene glycol was added to a 1 liter,
3 neck flask and stirred with a magnetic stirrer. Then, approximately 1.9 moles
(284 gm) of fumaryl chloride was placed in a separatory funnel and added
dropwise to the beaker containing propylene glycol. The addition rate was
adjusted to control the rate of HCI production, which would become violent if the
fumaryl chloride addition rate was too fast. The total volume of fumaryl chloride
was added over 4 hours, and the reaction mixture was stirred for an additional 1
hour. The product of this reaction is bis-(hydroxypropyl) fumarate trimer and
unreacted propylene glycol. This product is the starting mixture for the second
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reaction.
The second reaction is a transesterification ofbis- (hydroxypropyl
fumarate) to produce poly (propylene fumarate). The proposed reaction
mechanism appears in Figure 2-2. The transesterification produces one molecule
of propylene glycol for every ester linkage made. The condensate thus contains
the excess unreacted propylene glycol from the first reaction and propylene glycol
formed as the second reaction proceeds. The mixture of bis-(hydroxypropyl)
fumarate trimer and unreacted propylene glycol from the first reaction was placed
in a one liter glass reaction vessel (Ace Glass, Vineland, NJ). The reactor setup
appears in Figures 2-3 and 2-4. Figure 2-3 is a drawing of the entire system, and
Figure 2-4 is an enlargement of the reaction vessel, oil bath, and nitrogen inlet.
The reaction vessel was fitted with an electric mechanical stirrer, distillation head,
nitrogen inlet, and thermometer at the level of the condensation side arm of the
distillation head. A water cooled condenser, 30 cm long, was fitted to the
distillation head, and a graduated collector was placed at the outlet of the
condenser. The nitrogen inlet was connected to a Teflon bubble plate at the
bottom of the reaction vessel . The bubble plate was custom made in our
laboratory to fit the bottom of the 1 liter reaction vessel, and provided a constant
upward flow of nitrogen through the entire volume of the reaction mixture. This
helped to maintain uniform mixing as the polymerization progressed and the
viscosity increased. The nitrogen was supplied from a cylinder via a two stage
regulator. The nitrogen flow was adjusted so that steady streams of bubbles rose
through the polymerization mixture without spattering the reaction contents
throughout the 1 liter vessel. The polymerization temperature was controlled by
raising a heated oil bath (Instatherm, Ace Glass, Vineland, NJ) around the
reaction vessel. The reaction vessel and associated glassware were affixed to a
metal grid support system inside a fume hood. The oil bath was placed on a
scissor-type jack stand (Ace Glass, Vineland, NJ), heated to the desired reaction
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temperature, and raised onto the reaction vessel. The oil temperature was
controlled by a time proportional, digital temperature controller (Model 12106,
Ace Glass, Vineland, NJ) that used a platinum resistive temperature device (RTD)
sensor. The sensor was placed in the oil bath, not in the reaction vessel.
Experience with prior attempts to position the platinum RTD sensor inside the
reaction vessel demonstrated that rapid increases in polymer viscosity near the
end of the reaction occasionally damaged the stirrer and the RTD sensor. Hence,
reaction temperature was controlled by sensing the temperature of the oil bath that
surrounded the reaction vessel, and controlling the oil bath temperature to
+0. 1 C. The polymerization was performed in an inert nitrogen atmosphere to
exclude oxygen and water vapor. The nitrogen was preheated to the reaction
temperature by passing it through a ten foot length of coiled 0.25" copper tubing.
The tubing was immersed in the oil bath in the space between the reaction vessel
and the glass wall of the bath. The reaction pressure was controlled by a vacuum
pump (General Electric, Fort Wayne, IN) connected to the condensate receiver.
The pressure was monitored by a closed tube mercury manometer that was
connected to the line between the receiver and the vacuum pump. An adjustable
bleeder valve (a hose clamp on tubing that was open to atmospheric pressure and
connected to the vacuum line with a three way adapter) was used to control the
system pressure. Simultaneous adjustment of the bleeder valve and the nitrogen
flow rate allowed the attainment of reaction pressures down to 30 mmHg while
maintaining a steady flow of nitrogen bubbles through the reactants. A cold finger
vapor trap was immersed in liquid nitrogen between the condensate receiver and
the vacuum pump to protect the pump. The polymerization reaction will proceed
in the absence of catalyst, but it occurs much more rapidly with the addition of 2
to 3 weight percent antimony trioxide (Sb2O3) as a basic transesterification
catalyst. Transesterification reaction times to reach an equivalent molecular
weight polymer with and without catalyst are 8 hours and 76 hours respectively.
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The ability to polymerize in the absence of catalyst is attractive in view of this
polymer's intended biologic use, in that catalyst removal need not be verified in a
subsequent purification step.
The reaction began at 1600C and atmospheric pressure. When the rate of
condensate production decreased, the pressure was lowered to 30 mmHg. When
condensate production ceased at these conditions, the reaction was stopped by
lowering the oil bath and turning off the temperature controller. Prior experience
showed that further increases in temperature would effect gelation of the polymer.
The pressure was gradually returned to atmospheric while maintaining a positive
flow of nitrogen through the reaction vessel. The product, a yellow viscous
semisolid at room temperature, was removed from the reaction vessel, placed in a
sealed glass jar, and kept in a vacuum desiccator until needed for analysis.
The condensate from the reaction was distilled, and it boiled uniformly at 1860C
and atmospheric pressure. This is the boiling point of propylene glycol. The
polymer was purified by solution in THF and subsequent precipitation from
petroleum ether. This solution-precipitation sequence was performed three times.
The PPF is readily soluble in THF, and the antimony trioxide catalyst is not. The
polymer - THF solution is separated from the catalyst by decanting and filtering
it, and the polymer is recovered by precipitation from a nonsolvent (petroleum
ether). The precipitation is done by adding the available volume of polymer
solution slowly to a vigorously stirred beaker that contains approximately four
times that volume of petroleum ether.
The polymer was analyzed by multi-angle light scattering and size
exclusion chromatography (SEC) for determination of number average molecular
weight (M1), weight average molecular weight (M,,), and polydispersity index
(PDI). The light scattering data were collected on a MiniDawn multi-angle
detector (Wyatt Technology, Santa Barbara, CA), and gave an absolute estimate
of M1, which was used to calibrate the SEC instrument (Waters/Millipore,
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Milford, MA) using narrow band polystyrene standards. The Waters instrument
consisted of a Model 700 autoinjector, Model 600E pump, Model 996 photodiode
array detector, Model 410 refractive index detector, Ultrastyragel 7.8 mm x 300
mm column with and 10' A pore size (Waters/Millipore, Part #10572), a second,
linear Phenogel 7.8 mm x 300 mm column in series (Phenomenex, Part# 26973,
Torrance, CA), and a MilleniumTM 2010 control software system. The mobile
phase was tetrahydrofuran (THF), and data were gathered at a flow rate of 1
ml/min. The polymer was diluted to 0.5% in THF (w/v), passed through a 0.45gt
filter, and injected into the mobile phase in 50-100 gl aliquots for molecular
weight analysis.
Polymer analysis also included 'H -NMR and '3C-NMR, elemental
analysis, gas chromatography/mass spectrometry (GC/MS), and Fourier transform
infrared spectroscopy (FTIR). The FTIR spectroscopy was performed on a
Beckman 1000 spectrophotometer using sodium chloride plates or silver chloride
plates. Fourier transform proton nuclear magnetic resonance (FT/'H-NMR)
spectroscopy was performed on a Hitachi R-1500 spectrophotometer (60 mHz)
using 3% volume/volume concentrations with tetramethoxysilane (TMS) as a
standard in either deuterated chloroform (CDCl 3) or dimethylsulfoxide (d6-
DMSO). Carbon-13 nuclear magnetic resonance ('3C-NMR) were performed on a
JEOL FX270 convertible NMR spectrometer using CDC13 in concentrations of
1% for the proton NMR (270 MHz absorption frequency) and 10% for the '3C-
NMR (68.7 MHz absorption frequency) with TMS as a standard. Elemental
analyses and mass spectral data using a Perkin-Elmer 2400 Series 2 Elemental
Analyser and a Finnegan Model 4121C Gas Chromatogaph/Mass
Spectrophotometer (GC/MS) respectively.
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Results
The results of the two step reaction are presented separately for the
Schotten-Baumann reaction to form trimer, and the transesterification of trimer to
polymer. The trimer is a clear viscous liquid at room temperature and atmospheric
pressure. Elemental analysis revealed 40% carbon, 8.1% hydrogen, 8% chlorine,
and 43.9% oxygen. The theoretical values for elemental analysis are 51.7%
carbon, 7% hydrogen, 0% chlorine, and 41.3% oxygen. The difference between
the theoretical and calculated elemental analyses is explained by incomplete
conversion of fumaryl chloride to the diol trimer. The trimer is soluble in THF,
diethyl ether, and dichloromethane. The C-13 NMR data demonstrate the
presence of both diol trimer and half-product (6=19.2, 68.4, 76.6, 134.2, and 165
ppm). The half product (Figure 2-5) results from the reaction of a fumaryl
chloride molecule with one molecule of propylene glycol, leaving the second
chloride of the fumaryl chloride unreacted. The GC/MS data are consistent with
the presence of both trimer and half-product. Table 2-1 contains the GC/MS
values for the observed mass/charge ratios, and the proposed molecular fragments
that correspond to these data. These fragments are identified either as the diol
trimer molecule (T) minus a fragment (e.g. "T - C3H50"), or as the fragment itself
The product of the second reaction is a dark yellow to light brown
polymer that is nearly, but not quite, a solid at room temperature. The polymer
can be drawn into fibers as it is cooling from the reaction melt of 160 0 C to room
temperature. The molecular weight attained by stopping the reaction just prior to
gelation is Mn = 1534, Mb = 2714, with a polydispersity of 1.77. This point is
reached after 78 hours reaction time without catalyst. The same product is
attained after 23 hours reaction time in the presence of 2% Sb20 3 as catalyst. The
catalyst weight is calculated based on initial weight of trimer charged to the
reactor. Polymer molecular weight as a function of reaction time appears in
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Figure 2-6 for the catalyzed reaction. The SEC data that were used to construct
Figure 2-6 appear as Figures 2-7a, 2-7b, 2-7c, and 2-7d. Thermal analysis via
differential scanning calorimetry (Perkin Elmer Corp., heating rate = 100C/min,
calibration with indium standards) demonstrates a glass transition temperature at
-80C.
Table 2-1: GC/MS Data for Trimer
M/Z Fragment Structure
215 T-(OH)
193 Half Product (see Fig. 4)
175 T - (C3H50)
157 T - (OC 3H6OH)
99 T- (OC 3H6OH) - (C3H6O )
85 (C2H2COOCH 3)
71 (C2H2COOH)
59 (C3H6OH)
45 (C2H4OH)
Elemental analysis (Wright Laboratories, Wright-Patterson AFB, OH)
revealed the following composition: 51.3%C, 43.3%0, and 5.4%H (theoretical:
53.9% C, 40.8% 0, and 5.3% H). The FTIR spectrum (Figure 2-8) demonstrated
the expected absorbances (1000, 1200, 1250, 1650, 1720 and 3000 cmn ) for the
C-H stretch of the carbon-carbon double bond hydrogens, the C-O stretch, the
ester linkages, the trans carbon-carbon double bond at the a carbon to the ester
linkage, the carbonyl C-O stretch, and the C-H stretch. The polymer is soluble in
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THF. The mass spectral data for the PPF appear in Figure 2-9 and Table 2-2. The
actual spectrum is shown in Figure 2-9. Table 2-2 is constructed to show the
fragmented species associated with the observed charge to mass ratios in the
Table 2-2: GC/MS Data for Polymer
M/Z Fragment Structure
527 {HO(C 3H6OCOCH=CHOCO) 3C3H6}+
469 {HO(C 3H6OCOCH=CHOCO) 2C3H6OCOCH=CHC=O } +
441 {HO(C 3H6OCOCH=CHOCO) 2C3H6OCOCH=CH} t
389 {HO(C 3H60COCH=CHOCO) 2C3H6OH 2 }+
371 {HO(C 3H6OCOCH=CHOCO) 2C3H6})
313 (HOC 3H6OCOCH=CHOCOC 3H6OCOCH=CHC=O)'
285 (HOC3H6OCOCH=CHOCOC 3H6OCOCH=CH)
233 (HOC3H6OCOCH=CHOCOC 3H6OH 2) ÷
215 (HOC3H6OCOCH=CHOCOC 3H6,)
173 (HOC3H6OCOCH=CHOCOH2) +
157 (HOC 3H6OCOCH=CHC=O)
128 (OC 3H6OCOCH=CH)
99 (C3H6OCOCH) ÷
87 (C3H6OCOH)÷
82 (O=CCH=CHC=O) ÷
71 (COOC 2H3)+
59 (COOCH 3)÷
44 (CO 2)÷
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POLYMER MOLECULAR WEIGHT VS. TIME
Catalyzed Reaction
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REACTION TIME (HOURS)
Polymer Molecular Weight as a Function of Reaction Time
Figure 2-6
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SampleName
202-12A
Polymer Report
Date Acquired
09/13/94 12:29 PM
5.00 10.00
Minutes
Polymer Results
# SampleName Mn Mw MP Mz Polydispersity
1 202-12A 992 1315 1075 1790 1.325583
Size Exclusion Chromatography Data Used to Construct Figure 2-6
Figure 2-7a
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SampleName
202-12B
Polymer Report
Date Acquired
09/13/94 01:28 PM
/
I I
-4
5.00 10.00
Minutes
Polymer Results
# SampleName Mn Mw MP Mz Polydispersity
1 202-12B 1113 1553 1265 2212 1.394632
Size Exclusion Chromatography Data Used to Construct Figure 2-6
Figure 2-7b
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SampleName
202-12C
I I I I I
Polymer Report
Date Acquired
09/13/94 02:09 PM
I I I
5.00 10.00
Minutes
Polymer Results
# SampleName Mn Mw MP Mz Polydispersity
1 202-12C 1517 2457 1662 4726 1.619270
Size Exclusion Chromatography Data Used to Construct Figure 2-6
Figure 2-7c
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SampleName
202-12D
Polymer Report
Date Acquired
09/14/94 11:21 AM
I I I
10.00
Minutes
Polymer Results
# SampleName Mn Mw MP Mz Polydispersity
1 202-12D 1534 2714 1611 7504 1.769112
Size Exclusion Chromatography Data Used to Construct Figure 2-6
Figure 2-7d
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spectrum. The GC/MS captures only those fragments that are volatile. The largest
fragment observed was a heptamer ion at M/Z = 527. The GC/MS data are
consistent with the proposed polymeric structure of PPF.
The proton nuclear magnetic resonance data for the polymer appear in
Figure 2-10. The theoretical chemical shifts for the polymer repeating unit should
be a singlet at 6 = 6.8 ppm for the two trans hydrogens on the carbon - carbon
double bond, and a multiplet at 6= 2.0 - 0.6 ppm for the six alkyl hydrogens from
propylene glycol. The ratio of the two types of hydrogens in the polymer repeat
unit is thus 1:3. The area integration of the NMR peaks that correspond to these
hydrogens should bear the same ratio to each other. The observed spectrum
demonstrates an area under the 6 = 6.8 ppm peak of 0.327, and an area under the
6 = 2.0 - 0.6 peak of 0.831. These areas are in the ratio of 1:3. The multiplet peak
in the region 6 = 3.0 - 5.6 is due to the THF solvent protons.
Discussion
The sequential Schotten-Baumann and transesterification reactions
provide a simple, reproducible method to synthesize PPF. The analytical data
indicate that the polymer and the intermediate trimer have the proposed
structures. The FT-IR contains peaks that correspond to both the ester linkage and
the carbon - carbon double bond at the a carbon to the carbonyl group. The
possibility exists to prepare PPF without catalyst. This may be important should
the presence of even small amounts of catalyst become an issue in the intended
biologic use of PPF. The solid catalyst did precipitate out upon solution of PPF in
THF during the purification of PPF. However, the trade off would be the
increased reaction time necessary to synthesize PPF via the uncatalyzed route
versus the increased time and effort necessary to demonstrate that the catalyst had
been removed in syntheses that used it.
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There is a small percentage of chlorine that remains in the polymer after
reaction. The mass spectrometry data suggest that the chlorine is present as part of
a fumaryl chloride molecule which reacts with propylene glycol through only one
of its two chlorides. This was an unexpected finding, given the rapid nature of the
Schotten-Baumann reaction and the excess of propylene glycol in the reactants.
The presence of polymer that is terminated with a chloride may or may not be a
problem in the proposed biologic use of PPF.
The polymer that is synthesized via a catalyzed route undergoes
purification to remove the catalyst via solution in THF followed by precipitation
of the polymer from a nonsolvent, petroleum ether. The H-NMR data show trace
amounts of both THF and petroleum ether in product that is dried overnight in a
vacuum desiccator. These trace impurities may pose a problem for biologic use,
and experiments are underway to dry the product by rotary vaporization. . The
PPF polymer is soluble in both vinyl pyrrolidone monomer and methyl
methacrylate monomer. This is attractive, because vinyl pyrrolidone and methyl
methacrylate are two candidate monomers to polymerize in the presence of PPF.
Their chains can be crosslinked by the fumarate double bonds in PPF. This
proposed crosslinking via radical polymerization of the PPF double bonds permits
the formulation of a composite material based on PPF. The ability to make a
liquid solution of PPF in monomer facilitates the handling of the composite
material reactants. This is desirable for the intended polymerization of the
composite during a surgical procedure.
Conclusions
The synthesis of poly (propylene fumarate) in two steps via sequential
Schotten-Baumann and transesterification reactions is a straightforward,
reproducible method to make this polymer. The ability to produce polymer
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Proton Nuclear Magnetic Resonance Data for PPF Polymer
Figure 2-10
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without the need for extremes of temperature is an advantage over several
alternative synthesis routes. For example, prior stepwise polymerization methods
that used the diethyl or dimethyl ester of fumaric acid and propylene glycol as
monomers required temperatures up to 220 0 C to effect polymerization42'63. In
addition, side reactions such as ether formation were common, and premature
crosslinking often occurred throughout parts of the product polymer. The
synthesis presented here produces PPF that has a polydispersity index which
remains nearly constant over a range of molecular weights. This represents a more
reproducible reaction than prior synthesis methods. The purity of the condensate
collected in this two step scheme and the absence of other species upon analysis
of the product polymer suggest that this scheme produces a pure product for
subsequent inclusion in its intended composite material formulation.
The residual chlorine in both the trimer and polymer likely represents a
terminal, unreacted fumaryl chloride endgroup. This may or may not be
significant with respect to both biocompatibility and material property concerns in
the material's intended biologic use. Nevertheless, attempts will be made to attain
complete conversion of all fumaryl chloride to trimer in the first reaction step.
These include alterations in the monomer ratios, the monomer addition rate, and
the length of reaction.
The catalyzed second step allows the attainment of product that has Mw of
2714 g/mole after 23 hours of reaction. This is attractive, but brings the
requirement of insuring complete catalyst removal for the intended biologic use.
If in vitro and in vivo studies indicate promising mechanical and biologic
properties, then it will be necessary to either demonstrate complete catalyst
removal or revert to the longer, uncatalyzed transesterification reaction.
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CHAPTER 3
The Physical Characterization of Poly (propylene
fumarate) and Determination of its Mark -
Houwink Constants.
Introduction
The chemical characterization of poly (propylene fumarate) (PPF) was
presented in Chapter 2, and included size exclusion chromatography, elemental
analysis, infrared spectroscopy, nuclear magnetic resonance spectroscopy, mass
spectrometry, and light scattering analysis. The physical characterization of PPF,
presented in this chapter, includes differential scanning calorimetry (DSC),
thermogravimetric analysis (TGA), and dilute solution viscometry. The data from
dilute solution viscometry will be combined with previously collected light
scattering and size exclusion chromatography data to calculate the Mark-
Houwink constants for PPF. These constants, K and a, relate the intrinsic
viscosity of a dilute solution of the polymer to Mv, the polymer's viscosity
average molecular weight.
Materials and Methods
Thermoanalytical data were obtained using a TA Instruments Model 2910
Differential Scanning Calorimeter (DSC) at a scanning rate of AT=10 0 C/min up
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to 450'C in a nitrogen atmosphere. The cryogenic function of the DSC was used
to start the data collection at a temperature below room temperature. The nitrogen
source was purified, dried, and filtered. The nitrogen flow rate was 50 ml/min.
Calibration was performed with Indium standards. A typical sample for analysis
was approximately 12 mg of polymer in an aluminum specimen tray. A second,
empty aluminum specimen tray served as a control for the thermal measurements.
Weight loss in helium was determined on a TA Instruments Model 2950
Thermogravimetric analyzer (TGA) at a scan rate of AT=10 0 C/min up to 900 0C.
The helium flow rate was 50 ml/min, and a typical sample size of polymer for
analysis was 8 mg.
The viscosity measurements were performed with Ubbeholde Sizes 0 and
1 capillary viscometers (Fisher Scientific, Pittsburgh, PA). The data were
collected for pure tetrahydrofuran (THF) solvent, and for various dilute solutions
of PPF in THF. The solutions tested were 1%, 2%, and 3%. These were measured
on a weight per volume (w/v) basis: grams of polymer per milliliters of solvent.
For example, 0.25 grams of polymer dissolved in 25 ml of THF would be a 1%
solution. The measurements were performed in a constant temperature bath. The
bath was a ten gallon aquarium insulated on all four sides and on the top with one
inch thick styrofoam insulation. The bath was filled with water, and the water was
circulated through a heating-cooling unit which kept its temperature at 250 C +
0.01 C. The surface of the water was further insulated with floating air-filled
insulation spheres. The polymer solution to be tested was placed in the viscometer
and immersed in the water bath by connecting the viscometer to a lab stand and
clamp. The styrofoam insulation directly in front of the viscometer was
removable to permit data collection by visual inspection. After allowing the test
solution to equilibrate for thirty minutes in the constant temperature bath, the
solution was drawn up past the upper mark of the viscometer, and allowed to flow
through the capillary. The timer was started as the fluid meniscus passed the
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upper viscometer mark, and the timer was stopped as the meniscus passed the
lower mark. Each recorded data point, plus or minus its standard deviation, was
the average of four readings. Data were collected for PPF that had three different
molecular weights determined by size exclusion chromatography and light
scattering. The first sample had M= 1208 and M,= 1497, the second sample had
Mn = 1224 and Mb= 1904, and the third sample had M,= 1534 and M,= 2714.
Results
The DSC demonstrated a glass transition temperature (T) of -8 C. The
TGA showed a 4% weight loss due to solvent and propylene glycol (b.p.=187 0 C)
over the temperature range of 0-200' C. Pyrolysis of the PPF occurred at 277 0 C.
The DSC exotherm appears as Figure 3-1. The TGA data of temperature versus
weight loss appear as Figure 3-2.
The dilute solution viscosity data appear in Table 3-1 for the PPF polymer
having molecular weight MI = 1497, in Table 3-2 for the polymer having M =
1904, and in Table 3-3 for the polymer having M, = 2714. These data are the
elution time, in seconds, for the dilute polymer solution to flow between the etch
marks on the Ubbeholde viscometer versus the concentration, (C), of the dilute
polymer solution in grams polymer per ml solvent. The pure solvent is identified
as C= 0, and its elution time as to. The data were obtained for PPF in THF at 25'
C. The relative viscosity of each dilute polymer solution is the ratio of the elution
time of that solution to the elution time of pure solvent: Ir, = t/to. The specific
viscosity, sp,, equals one minus the relative viscosity (r, = 1 - rl). These are
both dimensionless quantities. The reduced viscosity, flred, equals the specific
viscosity divided by the dilute solution concentration. The reduced viscosity has
units of ml/g. The calculated values for these three viscosity parameters appear in
Table 3-4 for the PPF having M, = 1497, in Table 3-5 for the PPF having Mw =
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Table 3-1
Ubbeholde Viscometer Elution Times for PPF in THF at 25 C
Mw,= 1497 g/mole
Concentration, C (g/ml) Time , t (seconds)
0 to = 582.1 + 1.1
.01 600.6 ± 0.8
.02 626.2 ± 0.9
.03 651.2 ± 1.0
Table 3-2
Ubbeholde Viscometer Elution Times for PPF in THF at 25 C
M= 1904 g/mole
U
Concentration, C (g/ml) Time , t (seconds)
0 to = 374.8 ± 0.7
.01 385.7 ± 0.1
.02 402.3 ± 1.0
.03 412.4 ± 0.8
Table 3-3
Jbbeholde Viscometer Elution Times for PPF in THF at 25
M,= 2714 g/mole
Concentration, C (g/ml) Time, t (seconds)
0 to = 582.2 ± 1.1
.01 609.6 ± 1.0
.02 639.3 ± 0.9
.03 664.2 ± 1.9
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1904, and in Table 3-6 for the PPF having M. = 2714. The intrinsic viscosity of
the polymer, [q], is the limit, as the concentration approaches zero, of the reduced
viscosity. The graphs of the reduced viscosity versus concentration data of
Tables 3-4, 3-5, and 3-6 appear as Figure 3-3 for the PPF having Mw = 1497,
Figure 3-4 for the PPF having Mw, = 1904, and in Figure 3-5 for the PPF having
Mý = 2714. The extrapolation of these least squares fit lines to zero concentration
identifies the intrinsic viscosities of the three different molecular weight samples
of PPF. The intrinsic viscosity of the Mw = 1497 polymer is 2.67 ml/g, that of the
Mw = 1904 polymer is 2.97 ml/g, and that of the M, = 2714 polymer is 5.27 ml/g.
Figure 3-6 is a graph of log M, on the abscissa versus log [l ] on the
ordinate for the three molecular weights of PPF that had intrinsic viscosity
determinations made. The data that were used to construct Figure 3-6 appear in
Table 3-7, and the equation that describes a regression line fit to these data is:
log [TI] = log K + a x (log M) (Equation 3-1)
which can be rearranged to give:
[TI] = K x (Ma) (Equation 3-2)
where K and a are the Mark-Houwink constants for PPF in THF at 250 C. These
constants, calculated from a regression line fit to the data of Table 3-7, are:
K = 3.3 x 104 ml/g
a= 1.2
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Table 3-4
Relative, Specific, and Reduced Viscosities for Mw = 1497 g/mole PPF
C (g/ml) r ~= t/to lsp = r - 1 flred = sp/C (ml/g)
.01 1.03 i .003 .03 ± .003 3.0 + 0.3
.02 1.08 ± .004 .08 .004 4.0 + 0.2
.03 1.12 ± .003 .12 .003 4.0 + 0.1
Table 3-5
Relative, Specific, and Reduced Viscosities for M = 1904 g/mole PPF
C (g/ml) Tlr = t/to l sp 1l r 1 T red = 1sp/C (ml/g)
.01 1.03 + .002 .03 .002 3.0 + 0.2
.02 1.07 + .005 .07 .005 3.5 + 0.3
.03 1.10 + .004 .10 .004 3.3 + 0.1
Table 3-6
Relative, Specific, and Reduced Viscosities for M, = 2714 g/mole PPF
C (g/ml) ir= t/to 11sp r= i- 1 Tired= p/C (ml/g)
.01 1.05 ± .004 .05 .004 5.0 + 0.4
.02 1.10 + .004 .10 .004 5.0 + 0.2
.03 1.14 ± .005 .14 ± .005 4.6 ± 0.2
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Polymer Solution Concentration vs. Reduced Viscosity
M = 1497 g/mole
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Dilute Polymer Solution Concentration vs. Reduced Viscosity, M,=1497
Figure 3-3
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Polymer Solution Concentration vs. Reduced Viscosity
M = 1904 g/mole
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Polymer Solution Concentration vs. Reduced Viscosity
M = 2714 g/mole
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Dilute Polymer Solution Concentration vs. Reduced Viscosity, M,=2714
Figure 3-5
-89 -
E
0
C,)
0)
0)
.... II I I I . . . . . . . . . . . . . . . .
-90 -
Log (Molecular Weight PPF) vs. Log (Intrinsic Viscosity)
tI
T
T
-- x-axis is not continuous
r (~
93.18
1
3.28 3.43
Log MW (g/mole)
Graph of log M, vs. log [1I
Figure 3-6
91-
0.8 -
o(3)0C
L-04-
r-
-J
0.6 -
0.4-
0.2-
| | L- -
-92 -
Table 3-7
Polymer Molecular Weight vs. Intrinsic Viscosity for PPF in THF at 25 °C
M, (g/mole) log Mw  [n]] log [rl]
1497 3.18 2.67 .43
1904 3.28 2.97 .47
2714 3.43 5.27 .72
Discussion
Poly (propylene fumarate) in the molecular weight range 1497 < Mw <
2714 is a viscous semisolid at room temperature. It is readily soluble in methyl
methacrylate monomer and N-vinyl pyrrolidone monomer. These two monomers
are crosslinked by the fumarate double bonds of the PPF during the formation
of a particulate filled composite material based on PPF. The Mark-Houwink
exponent, a, is usually between 0.5 and 1.064. The value calculated here for PPF in
THF at 25 C, a = 1.2, may suggest that the PPF chains exist in THF solution in
short, stiff, rodlike configurations."'" Further work will include dilute solution
viscometry of narrow molecular weight PPF fractions to refine the Mark-
Houwink constant calculations.
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CHAPTER 4
The In Vitro Strength and Degradation
Characteristics of a Composite Material Based on
Poly (Propylene Fumarate)
Introduction
This chapter focuses on the formulation of poly (propylene fumarate) into
a particulate composite material, and the effect of several formula variations on
that material's in vitro mechanical properties. The composite material must
perform several functions in its intended role as a temporary bone substitute. It
must pass through a low viscosity stage during which it can be molded to fit an
arbitrarily shaped defect, harden over a time span of approximately ten to fifteen
minutes, and attain a compressive strength and modulus on the order of
magnitude of the trabecular bone that it will replace22 ,23 ,24 ,25. The need to have the
material harden during a surgical procedure motivates the strategy of radical
polymerization to crosslink a polymer through the fumarate double bonds of PPF.
N-vinylpyrrolidone was chosen as the monomer for this function. Poly
(vinylpyrrolidone) was used as a plasma expander during World War II, and has a
long history of being biocompatible67 . The radical initiation system chosen is the
initiator benzoyl peroxide and the accelerator N,N-dimethyl paratoluidine. This is
the same initiator-accelerator pair that is used in the clinical bone cement poly
(methyl methacrylate).
Material properties that would be attractive in a bone replacement
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composite, in addition to the strength criteria mentioned above, include porosity
to allow ingrowth of vessels and new bone, and an appropriate scaffold structure
upon which bone can grow. This work explores the use of 3-tricalcium phosphate
in the composite formulation as the osteoconductive scaffold to encourage bone
growth and potentially provide increased strength to the composite. sodium
chloride (NaCi) is used to function as a water soluble filler that will leach out
upon exposure to the body's aqueous environment and provide the composite with
initial porosity. Different molecular weights of PPF are used to assess whether
polymer molecular weight affects composite strength and modulus"4 . The ratios of
these various constituents to each other have been varied to assess the affect of
composite's composition on it's handling properties, strength, and modulus. The
handling properties are important because the composite, as it polymerizes, must
remain a coherent mass. It should be neither fluid nor powdery. Either of these
two extremes leads to loss of material from the intended site of application during
polymerization.
The variables described above have been systematically investigated via a
fractional factorial experimental design for their effect on composite strength,
modulus, and handling properties. These experiments are described next.
Materials and Methods
The five variables for the composite material formulation were examined
in a two level fractional factorial design. The material is a particulate filled
composite. It consists of a linear polyester, poly (propylene-fumarate) (PPF), that
is cross-linked through the fumarate double bond by a monomer, N-
vinylpyrrolidone (N-VP) (Sigma, St. Louis, MO), and filled with sodium chloride
(NaC1) (Sigma, St. Louis, MO) and p-tricalcium phosphate (p-TCP) (DePuy,
Warsaw, IN). The variables in the experimental design were: 1) the molecular
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weight of the PPF, 2) the ratio of the amount of sodium chloride (in grams) to the
amount of PPF, 3) the particle size range of the sodium chloride, 4) the ratio of
the amount of p-tricalcium phosphate (in grams) to the amount of PPF, and 5) the
ratio of the amount of N-VP (in grams) to the amount of PPF. The low and high
levels of the variables appear in Table 4-1. The fractional factorial design based
on these variables appears in Table 4-2. There are a total of eight runs in this
Resolution III design. A Resolution III experimental design will determine main
effects of the variables, but will confound main effects with two-factor
interactions 68. Each run is a combination of the "high" and "low" levels of the
variables listed in Table 4-1. These combinations of the variables are represented
by a "+" sign for "high" and a "-" sign for "low" in Table 4-2. Each batch of the
composite material was formulated on a basis of 4 grams of PPF. An example
recipe, calculated from Run #4 of Table 4-2, appears in Figure 4-1. In addition to
the variable components, each formulation also contains a radical polymerization
initiator, benzoyl peroxide (Sigma, St. Louis, MO), and an accelerator, N,N-
dimethyl paratoluidine (DMT) (Sigma, St. Louis, MO). Those formulations that
contained the "high" amount of N-vinylpyrrolidone received 0.18 grams of
benzoyl peroxide and 18 pl of DMT.
Table 4-1
High (+) and low (-) levels for the five variables in the fractional factorial design
M.W. PPF NaCl / PPF Particle Size p-TCP/ PPF N-VP/ PPF
High Level 2350g/mole 0.25 / 1 250-425 p 1.5 / 1 1.5 / 1
Low Level 1780g/mole 0 (no NaCl) 150-250 [t 0.75 / 1 0.75 / 1
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Table 4-2
Combinations of the Experimental Variables for the 8 Runs
M.W. PPF NaCI / PPF Particle P-TCP/PPF N-VP/PPF
Size
Run #1 +
Run #2 + +
Run #3 + + +
Run #4 - + + -
Run #5 - - - - +
Run #6 + + - + +
Run #7 - - + + +
Run #8 + + + - +
Recipe for Composite Formulation Run #4
4 grams PPF
1.0 gram NaCI (250 - 425 gm size)
3 grams N-vinylpyrrolidone
3 grams p - Tricalcium Phosphate
0.12 grams Benzoyl Peroxide
12 jil Dimethyltoluidine
Figure 4-1
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The formulations that contained the "low" amount of N-vinylpyrrolidone received
0.12 grams of benzoyl peroxide and 12 jl of DMT. Test specimens of the
composite material formulated from the eight combinations of variables listed in
Table 4-2 were made and analyzed in accordance with ASTM F451-86 for bone
cements. The test specimens are 6mm diameter by 12 mm high cylinders, and are
prepared by placing the polymerizing composite material into a 6 mm diameter by
12 mm high cylindrical Teflon mold. After hardening, and remaining in the mold
for 12 hours, the specimens are removed from the mold and tested in compression
on an Instron Model 1125 Materials Testing Machine. Prior to testing, the ends of
the specimens were ground with #600 grit sandpaper on an electric polisher. This
was done to produce plane parallel test specimens. The parallelism of the
specimen ends was assessed visually with the aid of the parallel arms of a
micrometer. Ten specimens of each of the eight formulations were tested for
initial strength and modulus. The Instron was fitted with a 5 kN load cell, and the
load measuring apparatus was zeroed, balanced, and calibrated. This was
accomplished by the electronic calibration system built into the load cell. The
specimens were compressed to failure at a crosshead speed of 1 mm/min, and the
load vs. deformation curve was recorded. These data were reduced to calculate
the Young's modulus (y) and ultimate compressive stress (a) for each
formulation. The load-deformation curves had a toe region and an identifiable
linear portion. A typical load-deformation curve appears as Figure 4-2. The
Young's modulus was calculated as the slope of the load-deformation curve in its
linear portion, and the ultimate compressive stress was calculated as the applied
load at failure divided by the measured cross-sectional area of the test specimen.
The composite formulation shown in Figure 4-1 was chosen for in vitro
assessment of degradation and the time course of material strength and modulus
under simulated physiologic conditions. This composition had both acceptable
initial strength and modulus for bone replacement, and good handling properties.
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Test specimens of this formulation were made as described above. Ten specimens
were made for testing at each of the following time points post-polymerization: 3
days, 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks. The test
specimens were removed from the Teflon mold after hardening, and were then
placed in a phosphate buffered saline (PBS) bath. The bath was kept at 37°C and
pH= 7.4. The saline solution was not changed during the experiment. At each of
the scheduled time points, ten specimens were removed from the bath and tested
on the Instron according to the above protocol.
Results
The results of initial compression testing for all eight combinations of
variables appear in Table 4-3. The mechanical testing was done one day after
placing the polymerizing composite material into the Teflon molds. Only Runs #
6 and 8 were too weak to be considered for further evaluation. We set a target
minimum compressive strength of about 5 MPa, and a minimum compressive
modulus of about 50 MPa as appropriate for a human trabecular bone replacement
material25. The effects of the five variables in the fractional factorial design on
the initial compressive strength and modulus of the resulting composite material
appear in Table 4-4. A positive number indicates that the particular variable had
an effect to increase the strength or modulus as it went from its "low" level to its
"high" level, and a negative number indicates that the variable caused the
strength or modulus to decrease as the variable went from its low level to its high
level. The presence of NaCI as a filler, the lower molecular weight PPF, and the
smaller amount of N-vinylpyrrolidone monomer had the strongest positive effects
on
compressive strength and compressive modulus. The larger amount of 3- TCP
had a strong positive effect on the compressive modulus. The strengths of the
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Table 4-3
In Vitro Compressive Strengths and Moduli
Initial Values, Prior to Degradation
Experiment # Strength, a Modulus, y
(MPa) ± s.d. (MPa) + s.d.
Run #1 4.3 ± 0.9 38.6 ± 3.6
Run #2 10.6 ± 0.9 138.3 ± 5.4
Run #3 4.7 ± 1.1 58.0 ± 10.6
Run #4 14.2 ± 1.9 67.4 ± 7.5
Run #5 5.5 ± 0.9 25.3 ± 3.6
Run #6 1.5 ± 0.5 17.8 ± 5.3
Run #7 4.6 ± 0.4 25.8 ± 1.3
Run #8 1.3 ± 0.5 12.8 ± 2.8
Table 4-4
Main Effects of the Experimental Variables on Material Strength and Modulus
Initial Values, Prior to Degradation
Variable Effect on Strength Effect on Modulus
(MPa) (MPa)
Presence of NaCl + 2.2 + 22.1
Size of NaCl when present + 0.7 - 14.0
Amount of N-VP - 5.2 - 55.2
Amount of p- TCP -1.0 + 24.0
Molecular Weight of PPF - 5.7 - 32.4
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composites were on the order of 5 MegaPascals (MPa), a magnitude appropriate
for consideration of the material as a temporary trabecular bone substitute.
The compressive strengths and moduli of the composite material after
exposure to phosphate buffered saline solution at 37°C and pH = 7.4 for the six
time periods studied appear in Table 4-5. The data appear graphically in Figure 4-
3 for the strength vs. time relationship, and in Figure 4-4 for the modulus vs. time
relationship. Figure 4-5 is a scanning electron micrograph of the surface of a
specimen that had been in the phosphate buffered saline for one week. The
irregularly shaped crevices are of the same magnitude as the sieved NaCI
particles, and likely represent the sites from which the salt has leached out.
Table 4-5
Degradation Data for Composite in PBS over Twelve Weeks
Time in PBS Strength (MPa) Modulus,y (MPa) Diameter (mm)
3 days 9.1 ± 0.7 149 ± 21 5.6 ± .22
6 days 8.7 ± 2.4 156 ± 54 5.8 ± .14
2 weeks 11.1 ± 1.8 226 ± 46 5.6 ± .14
3 weeks 10.9 ± 1.8 241 ± 78 5.6 ± .10
4 weeks 20.9 ± 3.7 590 ± 150 5.6 ± .08
6 weeks 27.1 ± 4.1 690 ± 74 5.4 ± .09
8 weeks 17.3 ± 2.1 420 + 82 5.6 ± .07
12 weeks 21.3 ± 0.4 696 ± 53 5.6 ± .08
Discussion
The in vitro mechanical strength results demonstrate that increasing the
molecular weight of the PPF did not increase the compressive strength of the
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Composite Compressive Strength vs. Degradation Time
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Composite Compressive Modulus vs. Degradation Time
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Scanning Electron Micrograph of In Vitro Degradation Specimen
Figure 4-5
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composite material that is based upon the PPF. Since, in general, the mechanical
properties of polymers improve with increasing molecular weight, this result is
not obvious at first glance. However, the mechanical properties in question here
are those of the composite material, not those of the base polymer. The
compressive strength and modulus of the particulate composite are more likely to
be affected by the nature and quantity of the cross links formed between the
double bonds of the PPF and the N-vinylpyrrolidone, and less dependant upon the
molecular weight of the PPF. One possible explanation for the inverse
relationship between PPF molecular weight and composite strength is that the
lower molecular weight polymer has a conformation such that its molecular size
is smaller than that of the larger molecular weight polymer. Thus, a given weight
of the lower molecular weight polymer would contain a larger number of
molecules than an equal weight of the higher molecular weight polymer. The
greater number of molecules per given weight would manifest itself as a larger
surface area per mass. This could expose more potential crosslinking sites (i.e.
fumarate double bonds) at the polymer surface in the case of the lower molecular
weight PPF compared to the higher molecular weight PPF, and account for the
observed strengths..
The NaCl was included in the composite formulation with the intent that it
would leach out in the body's aqueous environment, and thus create an initial
porosity into which granulation tissue and new bone could grow. Therefore, if the
NaCl has the effect of acting as a filler to increase the initial mechanical strength,
as demonstrated in this study, that increase may be short lived as the salt leaches
out.
The specimen diameter decreased over the first several days in phosphate
buffered saline, and then remained essentially constant for the remainder of the
study. The scanning electron micrograph in Figure 4-5 shows crevices in the
specimen, but there is no evidence that an interconnected porous network
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develops. The maintenance of specimen diameter raises the question of whether
the composite degrades in this in vitro simulated physiologic environment. As
will be shown in the next chapter, there is clear evidence that the composite
degrades in vivo in a rat model. The polymer may degrade in vitro over a longer
time span than it does in vivo. Such a difference would suggest that enzymatic
mechanisms in vivo supplement the hydrolytic degradation of the ester linkages.
The modulus increases steadily over the course of the twelve weeks. This
phenomenon can be explained by postulating that ester linkages hydrolyze, PPF
chains become shorter, and the shortened chains function as a filler that increases
the composite modulus. The trend of strength increase over the twelve weeks may
suggest that crosslinking continues to occur between PPF fumarate units and poly
(vinylpyrrolidone) chains. This observation will be investigated by performing
high performance liquid chromatography analysis of the phosphate buffered
saline at intervals during composite degradation to determine the products of the
degradation process. In addition, dynamic swelling experiments will be done to
characterize the change of the crosslink density with time. The degradation will
be allowed to continue longer than twelve weeks to assess whether, and over what
time period, the specimens will decrease in size.
Conclusions
1. The composite material's initial compressive strength and modulus in vitro are
of a magnitude appropriate for consideration as a temporary replacement for
human trabecular bone.
2. The composite material's compressive strength and modulus maintain the above
referenced appropriate magnitude in a simulated physiologic environment for
twelve weeks.
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CHAPTER 5
The Ingrowth of New Bone Tissue and Initial
Mechanical Properties of a Degrading Polymeric
Composite Scaffold.
Introduction
The motivation for temporary bone replacement is to exploit bone's
inherent self healing ability by developing a material that can provide structural
support to a region of the skeleton and be biocompatible, degrading in a
controlled fashion into non-toxic substances that the body can eliminate via
normal metabolic pathways. The data presented in Chapter 4 demonstrated that a
particulate composite based on PPF attains a strength and modulus that are
appropriate to perform the mechanical function of trabecular bone. The material's
strength and modulus were maintained over twelve weeks in a simulated
physiologic environment. The work presented in this chapter addresses two
questions: will the composite material degrade in vivo, and will new bone occur
in a skeletal defect that is reconstructed with the material? In addition, the
histologic evaluation of the specimens will give information concerning the
presence or absence of a local inflammatory response to the material, and thus an
estimate of its short term biocompatibility. One of the concerns regarding the
current nondegradable Orthopaedic bone cement, poly (methylmethacrylate), is
that it lowers the infection threshold of the region into which it is placed69'70 . The
assessment of a new material's propensity to incite inflammation at an
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implantation site is of significant interest to the clinician. A synthetic material,
regardless of its level of biocompatibility, functions as a foreign body and
excludes the host's infection fighting system from accessing the region in which it
resides. The eventual disappearance of a temporary replacement material, and the
reconstitution of the implantation site with normal host tissue is an attractive
feature of biodegradable reconstruction materials.
Materials and Methods
The experimental design separates the in vivo work into two parts. In the
first in vivo part of the study, five variables for the composite material
formulation were examined in a two level fractional factorial design. This is the
same design that was used for the assessment of in vitro mechanical properties in
Chapter 4. The variables in the experimental design are: 1) the molecular weight
of the PPF, 2) the ratio of the amount of sodium chloride (in grams) to the amount
of PPF, 3) the particle size range of the sodium chloride, 4) the ratio of the
amount of p-tricalcium phosphate (in grams) to the amount of PPF, and 5) the
ratio of the amount of N-VP (in grams) to the amount of PPF. The low and high
levels of the variables appear in Table 4-1. The fractional factorial design based
on these variables appears in Table 4-2. Each batch of the composite material
was formulated on a basis of 4 grams of PPF. In addition to the components
which varied according to the experimental design, each formulation also
contains a radical polymerization initiator, benzoyl peroxide (Sigma, St. Louis,
MO), and an accelerator (N,N-dimethyl para-toluidine) (DMT) (Sigma, St. Louis,
MO). Those formulations that contained the "high" amount of N-vinylpyrrolidone
received 0.18 grams of benzoyl peroxide and 18 gl of DMT. The formulations
that contained the "low" amount of N-vinylpyrrolidone received 0.12 grams of
benzoyl peroxide and 12 tl of DMT. These are the same amounts of initiator and
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accelerator that were used in the in vitro study of Chapter 4.
These material formulations were placed in a rat proximal tibial model,
and were all harvested at four weeks post surgery. The rat surgery was reviewed
and approved by the appropriate institutional animal use and care committee.
Humane treatment of these experimental animals in accordance with NIH
guidelines was observed at all times.
The model involves anesthetizing a 250-500 gram Sprague-Dawley rat
via inhalational methoxyflurane (Metofane®, 100%, Pittman-Moore Co.),
shaving the lower extremity, prepping it with Betadine, and draping it into a
sterile surgical field. No preoperative antibiotics are given71 . The surgeon then
makes a medial surgical approach to the proximal tibia and exposes it
subperiosteally. A 2 mm drill hole is made through the medial cortex and
trabecular bone of the proximal tibia. The hole does not continue through the
lateral cortex. The hole is made approximately 3-4 mm distal to the physeal scar
of the proximal tibia and the long axis of the drill hole is perpendicular to the long
axis of the tibia. This model has been used successfully to test bone replacement
materials for Orthopaedic applications7 2. The specimen for implantation has either
been prepolymerized in a Teflon mold, or is polymerized at surgery within the
bony defect in the rat tibia. The prepolymerized specimens are right circular
cylinders that have a diameter of 2 mm and a height of 4 mm. Each formulation
was placed in rat tibiae two ways: previously polymerized cylinders and
polymerization in situ within the bony defect. We added this in situ
polymerization portion to the study in order to assess whether the handling
properties and histologic characteristics of the composite material would be
affected by employing an implantation technique that more closely approximates
actual surgical conditions. The components of the composite material that were
polymerized in situ were sterilized by exposure to ultraviolet radiation for 12
hours. Each preparation method (prepolymerized or in situ) of each formulation
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was placed into two rats. Therefore, part one of the study used 32 rats. The
different formulations were evaluated for handling properties at surgery, bone
ingrowth on histologic cross-sections, and for the extent, if any, of an
inflammatory response. Representative histologic sections from part one of this
study appear in Figures 5-2 and 5-3.
The second in vivo part of the study used the best formulation from part
one (based on handling properties during polymerization and ingrowth on
histologic examination), and specimens made from this formulation were placed
into rat proximal tibiae. The formulation appears in Figure 5-1. The specimens
Recipe for Part Two of Study: Ingrowth vs. Time
4 grams PPF
6 grams N-vinylpyrrolidone
6 grams p - Tricalcium Phosphate
0.18 grams Benzoyl Peroxide
6 gl Dimethyltoluidine
Figure 5-1
from part two of the study were harvested at 1 day, 3 days, 1 week, 2 weeks, 4
weeks, and 5 weeks post implantation. The histologic sections from the ingrowth
vs. time implantations appear in Figures 5-4, 5-5, 5-6, and 5-7. There were 22 rats
used in this part of the study. Nine rats had prepolymerized specimens implanted,
and nine rats had the material polymerized in situ. We desired one rat per time
period, and chose the quantity nine per group to mitigate against unexpected
deaths as the longer time periods were approached. The observable quantities
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Low power hematoxylin and eosin stained specimen at four weeks from rat in
part one of study, demonstrating bone ingrowth into tibial defect previously
filled by composite material. Arrow points to junction between newly formed
woven bone and previously existing host bone. Arrowhead points to
degrading polymer. Star overlies region of new bone surrounding degrading
polymer. Original magnification is 2.5
Figure 5-2
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High power view of same section as Figure 5-2, demonstrating trabeculum of
woven bone in close apposition to polymer (solid arrow) and P-TCP (open
arrow). Original magnification is 10.
Figure 5-3
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Hematoxylin and eosin stained section from rat in part two of the study to
demonstrate surgical anatomy. Anterior tibial cortex (wide arrow), posterior
tibial cortex (arrowhead), marrow elements (star), boundary of original 2mm
diameter defect (narrow arrow). Plane of section is parallel to long axis of
tibia. Original magnification is 1.6.
Figure 5-4
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Hematoxylin and eosin stained section from part two of the study, 1 week
post implantation. Arrow points to advancing edge of new bone.
Original magnification is 4
Figure 5-5
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Same formulation and stain as Figure 5-5; specimen is 2 weeks post
implantation. Original magnification is 10. Trabeculae of woven bone (solid
arrow) have ingrown between degrading composite material (open arrow).
Figure 5-6
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Same formulation and stain as Figure 5-5; specimen is 5 weeks post
implantation. Original magnification is 10. New woven bone in intimate
approximation to degrading material
Figure 5-7
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were the same in this part of the study as they were in part one: material handling
properties, histologic assessment of material degradation and bone ingrowth, and
histologic evaluation of the composite's overall biocompatibility. One additional
rat was added to the 3 day, 1 week, 2 week, and 4 week time groups to serve as a
control for normal fracture healing of this bony defect. These rats had the same
approach and 2 mm defect made in their proximal tibiae, but nothing was placed
into the defect. There were 4 control rats.
The rats were euthanized at the appropriate time post surgery via
administration of methoxyflurane inhalational anesthesia followed by guillotine
decapitation. The entire tibia was harvested, cleaned of all soft tissues, and placed
in 10% neutral buffered formalin. The tibiae were then placed in decalcification
solution (TBD-2®, Shandon Instruments, Sewickley, PA) for 72 hours,
dehydrated in a series of increasing concentrations of ethanol solution, embedded
in paraffin, sectioned on a microtome parallel to the circular cross section of the
cylindrical tibial defect, and stained with hematoxylin and eosin. Several sections
were also prepared with a Von Kossa stain to assess the presence and distribution
of residual calcific deposits within the experimental cross sectional area.
Results
The rats from part one of this study were all euthanized at four weeks post
surgery. The different formulations of the material varied in their handling
properties for the in situ polymerizations. Runs #2, 3, 6, and 7 handled well. That
is, the components formed a homogeneous mass upon mixing, increased their
viscosity with time such that the polymerizing mixture could be inserted into the
bony defect, and hardened on the order of 5 - 10 minutes post mixing. The other
formulations did not handle well. They either did not harden by 20 minutes, or
they did not form a homogeneous mass that could be handled without crumbling
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and loss of particulates.
Histologic analysis showed that the formulation with the most extensive
bone ingrowth at 4 weeks was Run #7. Representative hematoxylin and eosin
sections of this formulation appeared in Figures 5-2 and 5-3. Therefore, since this
formulation also demonstrated good handling properties, and had an acceptable
initial strength and modulus, we chose it as the formulation for the ingrowth vs.
time experiment in part two of the in vivo study.
The histologic sections from the ingrowth vs. time implantations appeared
in Figures 5-4, 5-5, 5-6, and 5-7. There is progressively more of the cross section
occupied by bone as the implantation time increases from 1 day to 5 weeks post
surgery. The new bone is woven bone histologically, and the junction between the
woven bone and older lamellar bone can be seen at the margins of the circular
cross section originally occupied by the implant material. There is intimate
incorporation of the implant into the host bone defect created at surgery. The light
staining irregularly shaped areas in the hematoxlyn and eosin sections
demonstrate strong staining affinity with the Von Kossa preparation. This
indicates that they contain calcium, and likely represent the P- TCP. There is an
absence of acute inflammatory cells in the vicinity of the implant. Osteoblasts,
osteoid, and new woven bone are in close apposition to the degrading material
without evidence of an acute or other adverse pathologic inflammatory response.
This situation existed in all the specimens retrieved, and suggests that the
material's biocompatibility is good in the short term.
The general nature of the new bone formation bears mentioning. The areas
of the implant closest to its outer circumference appear to be replaced before there
is bone in the interior of the implant, and the interior areas of the implant become
progressively more infiltrated with trabeculae of woven bone as time progresses.
The replacement of the material by bone appears to progress from the peripheral
surface towards the center of the circular cross section. The control rats had an
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organizing hematoma in the cylindrical defect by three days, a combination of
cartilage and woven bone at 1 week, and had essentially filled the defect with new
bone by 2 -3 weeks.
Discussion
The control rats had the entire cross section of the tibial defect filled with
an organizing hematoma at three days post surgery, and by the end of 2 - 3 weeks
the defects were completely filled with new bone. This model, therefore, is not a
model to determine whether or not a defect will heal in the presence of this
material, but a model to assess the interplay between degrading material and host
in a weight bearing location. The rats all appeared to demonstrate normal use of
their operated leg. They walked and climbed in their cages without preference to
operated vs. nonoperated hindlimb. We would have expected no change in the
appearance of the defect if it were filled with the non-degradable bone cement
poly (methylmethacrylate). The defects in this study, however, did change over
the four weeks of the first part of the study, and over the five weeks of the second
part of the study. The outer margins of the composite gradually receded, and new
bone appeared in their place. The material throughout the cross section of the
defect became infiltrated with fingerlike trabeculae of new woven bone as time
passed. The material was not responsible for the bone formation, but it degraded
in vivo, and it produced no foreign body inflammatory response to hinder the
normal process of fracture repair. In the future, delivery of bioactive molecules
from the material or delivery of osteoblasts and osteoid cultured on the material
may enhance bone growth in a surgical site where it would otherwise not occur.
The relatively greater degradation from the surface region compared to the
interior of the specimen is encouraging for the following reason. In its intended
use, this material will need to provide a reconstructed skeletal region with
-131-
adequate mechanical properties from the time of surgery, through the time that the
material degrades and the region reconstitutes itself with new bone, and until the
new bone provides the required mechanical strength. A material that degrades
uniformly throughout its volume may be more likely to exhibit a decrease in
mechanical properties since new bone must work its way into the interior from
cellular elements near the surface, leaving part of the interior degraded but not yet
filled with new bone. In addition, this would initially be mechanically weaker
woven bone as opposed to lamellar bone. Alternatively, a material that recedes
from its surface and has bone continually advance against that surface may allow
the remaining bulk of non-degraded material farther from the surface to retain its
mechanical properties and provide strength to the reconstructed region. An
alternative to this scenario would be osteoblast transplantation and culture
throughout the replacement material prior to insertion of that material into the
surgical site".
The in vivo studies in a rat proximal tibia model demonstrated
progressive growth of new bone against the receding surface of the degrading
material, and ingrowth of new bone trabeculae into the interior of the degrading
specimen. The specimen was also well integrated with the surrounding bone, with
no internal fibrosis. There was an absence of a foreign body inflammatory
response to the presence of this material over a five week time span. This material
may thus be an attractive candidate for temporary replacement of trabecular bone,
facilitating both osteoconduction and osteoinduction
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Conclusions
1. This composite material, based on the linear polyester poly (propylene-
fumarate), has handling properties at surgery that are similar in quality and in
hardening time to the widely used nondegradable Orthopaedic bone cement
poly (methylmethacrylate).
2. The short term biocompatibility of this composite material appears to be good,
as evidenced by the absence of an acute foreign body inflammatory response to its
presence in these experimental animals.
3. The composite material, placed in the rat proximal tibial model, demonstrates
progressive replacement of the degrading material with woven bone from the
periphery towards the center over five weeks.
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CHAPTER 6
Future Work on Synthetic Strategies Toward
Autologous Bone Regeneration.
The currently ongoing aspects of this work involve refinement of the
polymer synthesis reaction. The monomer ratios, monomer addition rates, and
reaction times are being investigated with the goal of removing all residual
chlorine. The addition of evolved gas analysis capability to our laboratory's FTIR
instrument will permit the identification of gaseous state reaction products in real
time. Thus, the IR gas cell will be placed in front of the condenser for future
synthesis runs, and the nature of the reaction products will be compared to the
expected species as the polymerization proceeds.
The product polymer, PPF, will undergo further characterization. The
trimer and polymer have been analyzed by light scattering, elemental analysis,
FTIR, size exclusion chromatography, and dilute solution viscometry. In addition,
the trimer has been characterized by gas chromatography/mass spectrometry
(GC/MS), and by both carbon and proton nuclear magnetic resonance
spectroscopy ("C-NMR and 'H-NMR). The GC/MS, 13C-NMR, and 'H-NMR
evaluations of the polymer are underway.
The PPF has several features that are attractive for its intended biologic
use. These have been mentioned previously, and include the biocompatible nature
of its component monomers, the fumarate double bond that permits subsequent
cross linking, and the ester linkage that forms the basis of its biodegradation. We
have been investigating several other polymers that either have been used
biologically or show promise for such use. Examples of these polymers include
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poly (L-lactic acid) (PLLA), poly (glycolic acid) (PGA), poly (lactic-co-glycolic
acid) (PLGA), poly (ethylene oxide) (PEO), polydioxanone (PDS), and various
polyimides. The PLLA, PGA, PLGA, and PDS polymers have been used
successfully for many years as degradable surgical sutures. The PEO class has
found use in blood circulation applications73' 74 . The polyimides have a double ring
structure that confers rigidity to them. Experiments are currently in progress to
copolymerize PPF with these classes of polymers, and to determine both the
chemical and physical properties of the resulting materials. The goal is to produce
materials that possess the attractive qualities of each polymer that is part of the
copolymer. Preliminary results with PPF-PEO and PPF-PLGA are encouraging6 3 .
The target application for PPF-PEO is prophylaxis against post-angioplasty re-
stenosis of coronary arterial disease. The copolymerization will attempt to exploit
the anti-thrombotic properties of PEO with the ability of PPF to cross link in situ.
This will be explored as a polymerizable, degradable stent for temporary
stabilization of dilated arteries. The PPF-PLGA will be used for osteoblast
attachment and migration studies. The PLGA has good osteoblast attachment
properties, but does not possess mechanical properties consistent with temporary
bone replacement applications 36,58. The copolymerization of PLGA with PPF will
attempt to exploit the good osteoblast attachment and migration characteristics of
PLGA with the good mechanical property characteristics of PPF. Currently, our
group uses rat calvarial osteoblasts for cell growth and attachment studies. Work
is currently underway to use human osteoblasts for these studies. The proposed
source of the human osteoblasts will be the femoral head of patients who undergo
total hip arthroplasty. The femoral head is a source of abundant trabecular bone,
and is discarded after the procedure that replaces its worn cartilage surface with a
prosthesis. This proposal is currently working its way through the appropriate
institutional review committees. It will need to pass critical review of issues
related to informed consent and the removal of human tissue from the hospital to
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the research laboratory. This is an important step, however, since the goal of our
osteoblast transplantation program is to eliminate the immunologic problems
associated with allograft. The strategy will be to harvest autograft osteoblasts,
culture them on degradable polymer scaffolds in the laboratory, and implant the
cell-polymer constructs back into the host.
The in vivo rat experiments that were completed in this work need to be
scaled up to a larger animal model. The rat proximal tibial model is a good model
to assess initial biocompatibility and ingrowth in a weight bearing location, but it
is not a critical size defect. The rat proximal tibial 2 mm defect will repair itself in
approximately two weeks time when left untreated. A critical size defect is one
that will not heal without treatment in the lifetime of the animal. Work is in
progress to evaluate our composite material in a goat model. The protocol has
been reviewed and approved by the institutional animal use and care committee.
The composite material will be placed in a cylindrical defect in the distal lateral
metaphysis of a goat knee. The specimen will be inserted in a defect created with
a jig attached to the lateral femur. The jig is a hole saw guide that has a metal
extension which contains screw holes. The jig is attached to the lateral femur with
screws, and a one centimeter diameter hole saw passes through the guide to
remove bone and create the trabecular defect. The screws that attach the jig to the
lateral femur are replaced in the femur after the jig is removed. They can then be
used at necropsy to reposition the jig in the same location, and harvest the bony
region that was reconstructed with the temporary composite material. This
specimen will be analyzed by bone histomorphometry for number of bone
trabeculae, width of bone trabeculae, and principal directionality of trabeculae7 5.
The reconstructed region will be tested mechanically for compressive strength
and modulus using the protocol described in Chapter 4.
The delivery of both drugs and bioactive molecules from this material will
be explored. The sustained local delivery of antibiotics to a skeletal site would
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represent an advantage over the current practice of formulating these antibiotics
into nondegradable poly (methylmethacrylate) (PMMA) beads. The beads deliver
the antibiotics from only the outer regions of the spherical bead, and must then be
removed at a second operation. Experiments are now underway to evaluate the in
vitro elution of several antibiotics from PPF and PPF-PEO polymers. The same
PPF-PEO copolymers will be evaluated as delivery vehicles for both retroviruses
and genetically engineered cells in an arterial stenosis model. In addition, plans
are being made to assess the loading and delivery characteristics of bone
morphogenetic protein-2 (BMP-2) from PPF and a composite material that
contains PPF. The biologic activity of BMP-2 under conditions of loading into a
degradable polymer and sustained delivery from that polymer will need to be
assessed. If the BMP-2 retains its activity, then it may serve to direct bone
formation in locations where the composite material degrades and exposes the
BMP.
There is one further area of planned future studies that should be discussed
here. The intended use of the degradable composite material described in this
thesis will be to provide temporary mechanical strength and conditions for new
bone growth into a skeletal region deficient in trabecular bone. This use will
require compressive strength and modulus similar to trabecular bone. This
material will not be required to resist tensile or shear forces. The extension of this
work to include temporary replacement of compact bone will require the
consideration of both tensile and shear forces. In addition, structures of various
shapes will need to be fabricated to replace various anatomic parts of the skeleton
that contain compact bone. Copolymerization experiments are underway to form
poly (ester-co-imides), with the expectation of exploiting the rigid planar imide
linkage as a source of increased strength. The in vitro growth of osteoblasts onto
these new polymers is being explored. The goal will be a composite material with
a desired shape that contains viable autologous osteoblasts, so that the cell-
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polymer construct can be implanted in the deficient location. The desired end
result, as it is in this work, will be to replace the degrading implant with new host
bone that can then remodel along lines of local stress. The synthetic parts of the
construct should degrade and be excreted or metabolized by the body.
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